预约演示
更新于：2026-05-15
Amphotericin B
两性霉素B
更新于：2026-05-15
概要
基本信息
药物类型 小分子化药 |
别名 AmB、HC1507G2、SinuNase + [16] |
作用方式 调节剂 |
作用机制 Ergosterol 调节剂(麦角固醇 调节剂) |
非在研适应症 |
最高研发阶段批准上市 |
首次获批日期 (1958-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评孤儿药 (美国)、合格传染病产品 (美国)、孤儿药 (欧盟)、快速通道 (美国) |
登录后查看时间轴
结构/序列
分子式C47H73NO17 |
InChIKeyAPKFDSVGJQXUKY-INPOYWNPSA-N |
CAS号1397-89-3 |
关联
141
项与 两性霉素B 相关的临床试验NCT06525389
Liposomal Amphotericin B and Flucytosine Antifungal Strategy for Talaromycosis (LAmB-FAST)
LAmB-FAST is a factorial randomized controlled trial simultaneously testing two interventions in one trial. LAmB-FAST seeks to inform treatment guidelines on the induction and maintenance therapy of HIV-associated talaromycosis (formerly called penicilliosis) and will answer the following three questions:
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?
1. Is induction therapy using a single 10 mg/kg dose of liposomal amphotericin B (LAmB) is more effective than 14 days of the conventional deoxycholate amphotericin B (DAmB)?
2. Is adding flucytosine (5FC) to amphotericin B more effective than amphotericin B alone?
3. Is HIV viral load guided stopping of itraconazole maintenance therapy as effective as the current CD4 guided strategy in the prevention of talaromycosis relapse?
开始日期2026-07-01 |
申办/合作机构  Duke University [+4] |
NCT07559032
A Multicenter, Prospective, Observational Study to Evaluate the Efficacy and Safety of Amphotericin B in the Treatment of Breakthrough Invasive Fungal Disease in Hematological Patients Receiving Triazole Prophylaxis
The goal of this clinical trial is to learn if amphotericin B works to treat breakthrough invasive fungal disease (IFD) in patients with hematological diseases who have received azole-based prophylaxis. It will also learn about the safety of amphotericin B in this population.
The main questions it aims to answer are:
1. What is the overall response rate (complete remission + partial remission) of amphotericin B in treating breakthrough IFD after azole prophylaxis?
2. What medical problems do participants have when taking amphotericin B?
3. What is the 6-week (42-day) overall survival rate after starting treatment?
This is a single-arm, prospective study. Participants will:
1. Receive intravenous liposomal amphotericin B (3-5 mg/kg daily) for 4-6 weeks.
2. Undergo weekly clinical and laboratory assessments, including serum G/GM tests, microbiology tests, and imaging (CT) at 2, 4, and 6 weeks.
3. Have safety monitoring including liver and kidney function, electrolytes, and ECG.
4. Be followed for treatment response and survival.
The main questions it aims to answer are:
1. What is the overall response rate (complete remission + partial remission) of amphotericin B in treating breakthrough IFD after azole prophylaxis?
2. What medical problems do participants have when taking amphotericin B?
3. What is the 6-week (42-day) overall survival rate after starting treatment?
This is a single-arm, prospective study. Participants will:
1. Receive intravenous liposomal amphotericin B (3-5 mg/kg daily) for 4-6 weeks.
2. Undergo weekly clinical and laboratory assessments, including serum G/GM tests, microbiology tests, and imaging (CT) at 2, 4, and 6 weeks.
3. Have safety monitoring including liver and kidney function, electrolytes, and ECG.
4. Be followed for treatment response and survival.
开始日期2026-04-01 |
申办/合作机构 |
NCT07532850
Study on the Pharmacokinetic Characteristics, Safety, and Efficacy of Liposomal Amphotericin B in Critically Ill Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy
The goal of this prospective study is to describe the pharmacokinetic characteristics of liposomal amphotericin B during plasma exchange therapy for severe invasive fungal infections in Chinese patients, preliminarily explore the influencing factors of in vivo exposure variability of liposomal amphotericin B, and integrate the findings with efficacy and safety outcomes.
The main questions it aims to answer is: Clarifying the correlation between the concentration, efficacy, and safety of different forms of liposomal amphotericin B in a special population, explore the changes in drug concentration mediated by plasma exchange, elucidate the mechanism of individual differences in efficacy and the optimal dosage, in order to provide a basis for personalized treatment of liposomal amphotericin B.
The study plans to collect pharmacokinetic samples from 10 adult (aged ≥ 18 years) severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.
The main questions it aims to answer is: Clarifying the correlation between the concentration, efficacy, and safety of different forms of liposomal amphotericin B in a special population, explore the changes in drug concentration mediated by plasma exchange, elucidate the mechanism of individual differences in efficacy and the optimal dosage, in order to provide a basis for personalized treatment of liposomal amphotericin B.
The study plans to collect pharmacokinetic samples from 10 adult (aged ≥ 18 years) severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.
开始日期2026-03-30 |
申办/合作机构- |
100 项与 两性霉素B 相关的临床结果
登录后查看更多信息
100 项与 两性霉素B 相关的转化医学
登录后查看更多信息
100 项与 两性霉素B 相关的专利（医药）
登录后查看更多信息
22,485
项与 两性霉素B 相关的文献（医药）2026-12-31·Virulence
The cyclin dependent kinase (CDK)7 inhibitor BS-181 inhibits pathogenic Cryptococcus species, causing G
2
/M arrest and a splicing defect
Article
作者: Bowring, Bethany ; Hewitt, Kim ; Chen, Sharon C-A ; Halliday, Catriona L ; Sethiya, Pooja ; Dinh, Hue ; Djordjevic, Julianne Teresa ; Parsania, Chirag ; Cain, Amy K ; Desmarini, Desmarini
The fungal priority pathogen and basidiomycete, Cryptococcus neoformans (Cn), causes lung and brain infection in predominantly immuno-compromised individuals and there is an urgent need for new treatment options. The pyrazolopyrimidine-based cyclin dependent kinase (CDK)7 inhibitor, BS-181, has anticancer properties, but its antifungal activity has not been investigated. We show that cryptococcal CDK7 more closely resembles the human enzyme than that of ascomycetes, and that BS-181 inhibits its activity. BS-181 inhibited growth of both Cn and Cryptococcus gattii (Cg), but not ascomycete fungi and delayed progression through the G2/M phase of the cell cycle. Transcriptomic analysis revealed that BS-181 induces splicing defects leading to elevated intron retention within the transcriptome and also suppresses translational processes. BS-181 displayed additive or synergistic activity with licensed antifungals against laboratory and clinical Cn and Cg strains, most notably with amphotericin B where synergy (2-4-fold reduction in the amphotericin B MIC) was achieved using low-sub micromolar concentrations of BS-181. Compared with either drug alone, BS-181-AmB combination therapy provided greater protection against Cn infection in a wax moth model (p ≤ 0.032) and extended survival of Cn-infected mice. These findings demonstrate that CDK7 inhibitors, already of interest as anticancer agents, could be repurposed to prevent or treat opportunistic fungal infections in cancer patients when combined with licensed antifungals limited by either toxicity or resistance.
2026-10-01·PARASITOLOGY INTERNATIONAL
Therapeutic efficacy of a novel immunotherapeutic formulation, combining a multi-epitope chimeric protein and Amphotericin B, in murine L. infantum infection
Article
作者: Moreira, Gabriel José Lucas ; Campos, Júlia Kelly ; Coelho, Eduardo Antonio Ferraz ; de Souza Dutra, Gabrielle Caroline ; Lage, Daniela Pagliara ; Roatt, Bruno Mendes ; Costa, Scarleth Silva ; Moura E Souza, Ana Clara ; Carvalho, Ana Maria Ravena Severino ; de Ávila, Ricardo Andrez Machado ; Eleutério, Níbia Mariana ; Souza, Thiago Miranda ; Dos Reis Cruz, Luiza ; Duarte, Mariana Costa ; Fernandes, Ana Paula Salles Moura ; Ribeiro, Naianda Rezende ; Menezes-Souza, Daniel
Leishmaniasis is a vector-borne parasitic disease caused by Leishmania protozoa. First-line treatment with pentavalent antimonials faces increasing resistance and significant toxicity. Amphotericin B is an effective second-line alternative but is also toxic and complex to administer, with a safer but expensive liposomal formulation. This study evaluated an immunotherapeutic approach using a chimeric protein composed of multiple T-cell epitopes from Leishmania (L.) infantum, combined with the adjuvant Monophosphoryl Lipid A (MPLA), in a murine model of VL. Our findings demonstrate that the combined rChi+MPLA/Amp-B therapy significantly outperformed monotherapies, inducing a robust TH1-polarized immune response. Splenocytes from this group exhibited markedly higher levels of TNF in both CD4+ (SC/CC = 1.64) and CD8+ T cells (SC/CC = 1.93) compared to Saline, MPLA, and rChi controls (p < 0.05). Furthermore, the combination therapy achieved a significantly higher IFN-γ/IL-10 ratio in CD4+ cells (Ratio = 2.03) compared to Saline, MPLA, and rChi groups (p < 0.05), indicating a shift away from the immunosuppressive environment characterized by high IL-10 levels in untreated Saline controls (SC/CC = 1.58). This protective environment was further corroborated by a marked elevation in nitric oxide (NO) levels in the rChi+MPLA/Amp-B group compared to all other experimental groups (p < 0.05). This potent immune activation correlated with a drastic reduction in parasite load. The rChi+MPLA/Amp-B group achieved statistically significant reductions (p < 0.05) of 98.4% in the lymph nodes, 99.1% in the spleen, and 97.8% in the liver compared to the Saline group. These reductions were also significantly superior (p < 0.05) to those observed in animals treated with Amp-B alone (82.1%, 89.3%, and 79.4%) or rChi+MPLA alone (75.2%, 68.5%, and 72.1%) in the lymph nodes, spleen, and liver, respectively. These results highlight the potential of the rChi+MPLA/Amp-B formulation as a highly effective immunotherapeutic strategy to enhance conventional chemotherapy and improve the clinical management of VL.
2026-10-01·PARASITOLOGY INTERNATIONAL
Comparative proteomic profiling reveals distinct molecular signatures of drug resistance in clinical isolates of Leishmania donovani
Article
作者: Gurjar, Dhiraj ; Sundar, Shyam ; Pai, Kalpana ; Bodhale, Neelam ; Saha, Baibaswata ; Ponte-Sucre, Alicia ; Saha, Bhaskar
Leishmaniasis remains a major public health concern, with treatment options limited to amphotericin B (AmpB), sodium stibogluconate (SSG), miltefosine, and paromomycin. Despite extensive clinical and field evaluations, the efficacy of these agents is increasingly undermined by toxicity, high cost, patient non-compliance, and the emergence of drug-resistance. Given this growing challenge, we conducted a comparative proteomic analysis of five Leishmania donovani clinical isolates: one drug-sensitive (BHU1066) and four drug-unresponsive to SSG (NS2), miltefosine (BHU1064), amphotericin B (BHU919), and paromomycin (BHU1020). Liquid chromatography-mass spectrometry identified proteins across these clinical isolates, with each drug-resistant isolate exhibiting a distinct profile of up-regulated proteins compared to the sensitive. Functional annotation revealed that genes involved in metabolic pathways, translation, RNA modification, chaperones, heat shock proteins, and signaling were prominently up-regulated in all drug-unresponsive clinical isolates. A subset of metabolic enzymes associated with glycolysis unique to Leishmania were consistently elevated, suggesting their potential role in mediating drug resistance. Approximately 20% of up-regulated proteins remain uncharacterized, highlighting novel candidates for future drug target discovery. Quantitative RT-PCR of selected differentially expressed genes confirmed significant drug-resistance-specific transcriptional modulation. These findings demonstrate that drug resistance in L. donovani is accompanied by extensive proteomic remodeling, emphasizing the need for comprehensive molecular studies to inform new therapeutic strategies against both drug-sensitive and drug-resistant leishmaniasis.
380
项与 两性霉素B 相关的新闻（医药）2026-05-14
·百奥信康
1. 引言
脂质纳米颗粒作为一种突破性的药物递送技术，在医疗保健领域展现出前所未有的变革潜力。这些药物载体引发了极大的关注，特别是在COVID‑19疫情期间开发mRNA疫苗的关键作用中。然而，脂质纳米颗粒的潜力不仅在于其当前应用，更在于一个未来，即个性化医疗利用脂质纳米颗粒平台来治疗众多疾病，这得益于其经济、可靠且可持续的生产。本文探讨了脂质纳米颗粒生产方面的创新如何通过提高药物疗效、扩大治疗可及性以及改善全球健康状况，引领医学进入一个新纪元。
脂质纳米颗粒在现代医学中的历史始于1960年代的基础研究，当时Alec Bangham首次表征了脂质体 [1]。然而，直到1995年，美国食品药品监督管理局才批准了首个脂质体药物递送系统Doxil® [2]。这种多柔比星制剂相比自由给药显示出心脏毒性降低，标志着化疗药物递送领域的重大进展。Doxil的成功推动了二十年的创新，到 2015 [3] 时已有超过十余种临床批准的脂质体产品，包括用于真菌感染的B型两性霉素制剂（AmBisome® [4]）以及用于白血病的长春新碱（Marqibo® [5]）。
2010年代带来了核酸递送的新前沿。2018年，食品药品监督管理局批准了ONPATTRO® [6] ——首个针对遗传性转甲状腺素蛋白淀粉样变性的基于脂质纳米颗粒的RNA干扰疗法。这一突破克服了小干扰RNA稳定化和靶向递送方面的挑战，证明了脂质纳米颗粒在小分子之外的潜力。随后，COVID‑19大流行使脂质纳米颗粒凭借mRNA疫苗（Comirnaty® [7] 和Spikevax® [8])一跃成为焦点，它们在全球2024 [9]接种的超13亿剂疫苗中占据了很大份额。这一全球性事件在人口规模上证明了其安全性与有效性，同时也暴露了批生产规模扩大方法在疫情应对中存在的制造局限性。早期脂质纳米颗粒（LNP）开发（1995–2010年）侧重于通过增强渗透与滞留效应（EPR）实现被动靶向。2010-2020年间，主动靶向策略在临床前试验中出现，配体偶联脂质纳米颗粒实现了组织特异性递送。脂质化学方面的进一步进展，特别是可电离脂质（如DLin‑MC3‑DMA），解决了内体逃逸这一难题，这对于实现成功的核酸递送 [10]至关重要。这些创新为当前新一代脂质纳米颗粒奠定了基础，后者正被设计用于提升递送特异性和治疗效果。
这种能力为治疗疾病开辟了新的可能性，而这些疾病传统上难以通过常规药物递送方法来应对。脂质纳米颗粒的脂质组成可以定制，以优化药物稳定性、细胞摄取和靶向递送，使其成为适用于多种医疗应用的理想载体[11]。尽管潜力巨大，但基于脂质纳米颗粒的疗法在生产与可扩展性方面仍面临挑战。大多数商业化制造工艺依赖于批生产方法，这些方法可能效率低下、成本高昂且难以扩展[12]。这些局限性是导致基于脂质纳米颗粒的疗法成本高昂的因素之一，限制了其普及，尤其是在世界相对欠发达的地区。必须解决这些制造挑战，才能充分释放脂质纳米颗粒的潜力并彻底革新医疗保健。
2.连续制造的进展
向先进制造技术的转变，例如脂质纳米颗粒的连续制造，代表了药品生产的重大变革。历史上，批式处理一直是主要的生产方法，其中会生产一定数量的产品在离散的单元操作中，通过存储分隔，并且通常在操作之间进行测试。批式脂质纳米颗粒生产涉及以下顺序步骤：脂质纳米颗粒形成、切向流过滤浓缩与缓冲液置换，随后进行生物负荷降低过滤、可选的后载药/表面修饰、冷冻保护剂添加与最终稀释，以及最终在灌装前进行无菌过滤。每个步骤都是一个独立的单元操作这需要不同的撬装设备和储罐，使得步骤间的手动切换耗时费力，因为下一步需要重新设置，因此存在更大的人为错误风险。批次周转时间因每台撬装设备都需要清洗、灭菌和预充程序而进一步延迟，所有这些都要求操作员干预。虽然大多数步骤过渡无需过程暂停测试即可进行，但某些阶段——例如冷冻保护剂添加和最终稀释——可能会因核酸浓度和包封率检测而延迟，这些检测可能需要数小时才能完成。总体而言，大规模批次LNP生产难以扩大规模，因为每件设备都必须针对新的规模进行开发，更容易出错，并且完成每批次都需要大量时间。相比之下，连续制造通过物料在数秒内完成这些相同步骤间的流转来简化生产，质量通过过程分析技术（PAT）实时验证，从而消除了过程中的暂停。这种不间断的封闭系统方法提供了显著优势，可能能够改变基于LNP的治疗性药物生产的格局。
连续制造的一个关键特性是能够在无需重大工艺变更的情况下调整生产规模，这可简化技术转移并缩短工艺验证所需的时间。这一优势在新药申请中尤为显著，连续制造有望缩短开发时间线并加快监管批准，这一点在2022年食品药品监督管理局对制药连续制造监管提交及结果的审查中得到印证[13]。除了最初的药物开发过程，连续制造还能让制造商更迅速地响应：i）满足市场需求中的正常波动；ii）缓解药物短缺[14]；以及iii）应对疫情情况。能够快速增加和减少生产能力，减少了昂贵的停机时间，也降低了因储存保质期相对较短的昂贵药品而产生的需求和费用。
连续制造系统的设计使得产品质量得以内置其中。质量源于设计原则被用于开发连续制造工艺，而过程分析技术通常涵盖所有关键产品质量属性和所有关键工艺步骤。这实现了对工艺参数的实时监测与调整，确保稳定的产品质量，并能在必要时中途分流或停止工艺。因此，因不符合规格而需丢弃整批产品的情况得以消除。相比之下，传统的批次加工依赖终点检测，因此检测失败会导致整批产品被拒收，这是一种重大且昂贵的浪费，可能导致药物短缺。连续制造中增强的过程控制（无需在步骤间等待检测）带来了稳定的产品质量、消除了批次间差异，并确保了监管合规性[15]。
连续制造为实现稳健、可扩展的核酸‑LNP生产提供了一个理想的解决方案。通常，连续工艺涉及更小的物料量，其相互作用的时间周期比大规模批次方法要短得多。这对于脂质类产品是有益的，因为大规模混合时混合器区域之间的流体流动模式差异更大[16]。流量、浊度和温度的微小差异会对LNP粒径和形成产生巨大影响，因此较小的系统更具可控性。连续制造将小规模混合的可控性与连续流相结合，只需改变运行时长，就能实现小批量或大批量的生产。额外的产能提升可以通过并行化或提高流速来实现，具体取决于混合器。然而，连续制造本质上对任何批次规模都更具灵活性。混合特性与过程分析技术相结合，可实现更高程度的过程控制，因为工艺参数可以根据实时数据进行微调。这确保了运行中每个环节的产品质量一致性，并为监管审批提供了完全过程控制的证据。极少的人工干预降低了错误和污染的风险，因为整个工艺被封闭在一个系统中。连续制造还最大限度地减少了步骤之间的停留时间（在秒级范围内），降低了LNP在脆弱阶段（例如溶剂去除步骤前，即颗粒形成后不久）不稳定的风险。因此，脂质纳米颗粒可以快速生成，并具备理想的关键质量属性。连续制造还通过合并步骤、最小化启动、拆卸和清洁时间，提高了效率，减少了设备尺寸并降低了能耗，从而提供了降低工艺成本的可能性。
脂质纳米颗粒的连续制造已有多种设计开始商业化。其中包括采用层流条件的微流体设备，通过通道几何结构混合乙醇和水相，脂质纳米颗粒在流体的界面处缓慢形成[17]。然而，微流体混合器在长时间运行时可能出现堵塞问题，并且由于通道较小，放大难度较高，尽管它们在实验室规模上可以可靠运行。采用更高流速的快速混合方法，例如乙醇和水相在倾斜交叉流或同向流中形成湍流液体射流，可以实现同等质量的脂质纳米颗粒，但需要精确控制流速和温度，这由过程分析技术实现。工艺放大可以通过提高流速和延长流动时间来实现，无需并行化，尽管每次实验需要更大的体积(>20 毫升)。最近的努力证明了这些技术的有效性，其关键质量属性与传统方法制成的参比制剂匹配甚至超越[18,19]。尽管许多公司现在提供微流体的小规模混合技术，但这些方法的连续性意味着制造效率的提升只有在下游步骤，如切向流过滤、缓冲液置换、冷冻保护剂添加、后装载和过滤等环节连接起来，并具备高流速能力的连续性时，才能完全实现。这样一个将所有单元操作整合的完全连续平台现在已在DIANT Pharma,Inc.商业化提供，其中过程控制和过程分析技术可集成到包含切向流过滤和无菌过滤单元的连续制造过程中，用于温度、流速和粒径的监控[20,21]。
3.个性化医疗
以往诸如病毒载体等基因递送平台，在免疫原性、载荷大小和生产时间较长方面存在困难[22]。脂质纳米颗粒解决了其中部分不足，当其与连续制造结合时，由此产生的灵活性和质量控制能够在创纪录的时间内为个体患者定制配方。这种个性化可延伸至纳米颗粒的脂质组成及其治疗载荷，从而实现优化药物递送，基于患者的基因图谱、疾病状态或其他个体因素。
快速生产患者特异性疗法的能力，在癌症治疗领域尤其具有变革性潜力。个性化癌症疫苗可以从检测癌细胞的验血开始，随后进行测序，再借助人工智能设计定制疫苗[23]。这种个性化疫苗随后可通过脂质纳米颗粒按需制造，专门递送至肿瘤细胞，有望彻底革新癌症免疫疗法。脂质纳米颗粒作为基因药物的递送载体也展现出巨大前景，其中包括诸如CRISPR‑Cas9等基因编辑技术。通过克服当前的递送挑战，脂质纳米颗粒技术有望让这些核酸疗法应用于更广泛的疾病，包括目前被视为无法治疗的遗传性疾病 [24]。将精确的基因编辑工具与高效的脂质纳米颗粒递送系统相结合，将为治疗遗传性疾病、癌症乃至像阿尔茨海默病这类复杂疾病开辟新前沿。
然而，将连续制造应用于个性化医疗并非没有挑战。为小批量、患者特异性生产建立连续制造基础设施的高昂初始成本可能是个问题，尤其是在需要频繁定制时。为每位患者调整制造工艺会增加运营复杂性，并需要先进的过程控制以维持不同配方下的产品质量。个性化治疗的监管途径仍不完善，通常需要为每个个性化产品进行额外的验证和监督。这些因素加上对专业劳动力培训的需求，意味着尽管连续制造为个性化医疗提供了巨大的潜力，但在实现广泛的临床实施之前，仍需克服实际和经济障碍。
4.可持续性
制药行业正越来越多地接纳可持续性和绿色化学原则，以应对其环境影响。连续制造的关键机遇包括：减少危险化学品和溶剂的使用；通过实时监测和调整来优化效率；以及利用计算机模拟方法（如数字孪生）来完善工艺流程。其他机遇，例如一次性使用系统，可以消除清洗需求从而减少水和能源消耗，但塑料废弃物仍是问题 [25]。清洁和灭菌程序可以通过以下方式改进：i) 利用过程分析技术监测清洁过程；ii) 为排水设计正确的坡度；iii) 为理想混合选择正确的管道直径；以及iv) 在整个系统中设置原位清洗/原位灭菌（CIP/SIP）开口以提高效率。清洁常被忽视，但它对减少停机时间和废弃物同样至关重要，尤其是在无菌性受损且备用设备不可用时。
5.经济影响
经济因素将在未来几年对制药制造产生重大影响，尤其是在连续制造的发展中至关重要。随着通货膨胀加剧、原材料成本上升以及需要对现代技术进行大量投资，所有制造类型都将受到影响。迫在眉睫的专利悬崖——预计在2023年至2028年间将使品牌药物销售面临约2000亿美元的损失——正迫使企业进行多元化，并制造或收购新的潜在重磅药物[26]。而数十年之久的研发时间线、不断变化的监管要求，以及向需要专业制造能力的复杂产品转变的现实，使得情况更加严峻。然而，新建造设施的高昂成本构成了采纳的重大障碍，特别是对于规模较小的公司或市场需求不确定的产品而言。在基础设施和劳动力培训上进行重大投资以支持运营和维护是必要的，但转型需要时间，且可能仅对新产品线可行。尽管如此，尽管面临挑战，采纳先进制造的潜在益处正变得不容忽视，尤其是在竞争日益激烈以及需要具备能在全球供应链中断时满足国家需求的国内制造能力的背景下。本质上，产业界必须在采纳新技术的重大前期成本和挑战，与提升效率、灵活性和可及性带来的长期效益之间取得平衡。
长期来看，连续制造可以通过模块化平台和提升生产效率[15]来缩短扩产时间和降低设施启动成本，从而减少基于脂质纳米颗粒的疗法的成本。通过更快速地应对市场需求波动，可以减少过期药物的库存积压，这在出现短缺或因新病原体引发的健康危机（此时快速响应是唯一选择）时尤为有用。一个能更好地满足市场需求的制造平台意味着更高的药物产品可及性和更可负担的药物。此外，分布式（本地化）制造的能力（通过连续制造实现）有潜力解决全球健康不平等问题，因为它能让中低收入国家更广泛地获得救命治疗。
6.挑战
除了巨大的前期投资，在优化连续制造过程以适应不同类型的脂质纳米颗粒和载荷材料方面，依然存在技术障碍。每种治疗应用可能需要具有独特生产要求的特定脂质纳米颗粒配方。针对肝外组织的脂质纳米颗粒表面靶向、安全有效的基因操作，以及将脂质纳米颗粒载荷递送至细胞核而非仅停留在细胞质的研究，也同样必要 [27]。开发能够适应这种多样性的柔性制造平台对于提升效率与降低成本至关重要，但决定脂质纳米颗粒生产可行性的许多因素并非只在于制造环节。CM采纳缓慢的一个主要原因在于运营和文化挑战，而这是由监管合规顾虑和层级官僚体制[28]驱动的。任何制造工艺或技术的变更都必须经历严格的验证和审批流程，这些流程耗时且昂贵。这催生了一种安全与谨慎的文化氛围，即便新技术可能带来巨大效益。此外，由于制造环节在整体药物研发管线成本中所占比例较低，以及制药公司传统上享有高利润率，优化制造工艺的紧迫性相对减弱。这与其他行业不同，在其他行业中效率提升对于维持竞争力至关重要。
监管不确定性一直是一项重大挑战，不过近期的一些努力，例如ICH Q13指南关于连续制造的发布，为实施提供了一个初步框架 [29]。然而，在全球监管协调、更新的药典标准、简化新型可电离脂质的法规方面，挑战与成本依然存在[30], 不同的单元操作的整合，以及稳健控制策略的开发方面也是如此。监管机构需要调整其指南以适应连续生产的独特特点，这需要时间，但能确保在促进创新的同时维持安全和有效性标准。
总的来说，这可能会使医疗保健从一个仅针对症状进行应对的体系转变为一个能够治愈新疾病并最终基于独特的个人特征实现预防医学的体系。短期内，持续生产能够通过克服初期投资后提供更高质量的药物，并减少短缺情况。但全面的益处将伴随着真正的端到端持续生产以及相应的质量管理体系才能实现。阻碍这一进程的不仅仅是生产问题；新的脂质纳米颗粒（LNP）载体要得到验证还需要很多年的时间，尤其是在基因编辑领域也是如此。其他瓶颈，如临床试验，可能需要从根本上重新考虑，特别是对于个性化疗法而言。然而，脂质纳米颗粒本身在疫情期间已被证明是一种安全且有效的递送平台，值得投资。
7.结论
脂质纳米颗粒的连续制造即将迎来制药制造乃至整个医疗保健领域的新时代。通过解决当前在可扩展性和成本方面的限制，这一技术进步和文化转变可以扩大创新疗法的可及性，实现对健康危机的快速响应，并赋能可能通向个性化医疗的基因治疗。最终，能够快速实现个性化医疗的微型生产套件或许可直接部署于医院，从而大幅提升可及性。这种向连续制造的转变是脱离传统批处理工艺的根本性变革，将带来目前无法实现的效率提升。
随着一个潜在新时代的到来，所有利益相关者——从研究人员和制药公司到监管机构和政策制定者——必须共同努力克服剩余的挑战。政府可以提供关键的资助激励，降低投资风险，并支持制定协调一致的全球监管指南。学术机构贡献基础研究、劳动力培训和验证新兴技术，确保创新既是证据驱动的，又是公开可用的。工业领域具备在工艺放大、质量保证以及商业化方面的能力，能够将实验室的成果转化为符合 GMP 标准的大规模生产。诸如公私合作项目和共享制造中心等合作举措能够加速脂质纳米颗粒技术的理解和开发，对各方都有益处。多部门合作对于建立强大的脂质纳米颗粒连续制造实践至关重要，并且对于改变对如何接纳能够改善公众健康的新技术的文化观念也非常重要。能够以经济、可靠且持续的方式生产脂质纳米颗粒不仅是一项制造创新，而且还是开启新型医疗保健方式的关键。随着脂质纳米颗粒共晶制造技术的不断进步，我们正朝着一个世界迈进，在这个世界里，前沿治疗不再是少数人的特权，而是对多数人的现实保障。
参考文献
1. Hou X, Zaks T, Langer R, et al. Lipid nanoparticles for mRNA delivery. Nat Rev Mater. 2021;6(12):1078–1094.
2. Ortho Biotech Products, LP. Doxil (doxorubicin HCl liposome injection) [package insert]. Bridgewater (NJ): Ortho Biotech Products, LP; 2007 May [cited 2025 Apr 17]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2007/050718s029lbl.pdf
3. Sercombe L, Veerati T, Moheimani F, et al. Liposomal formulations in clinical use: an updated review. Pharmaceutics. 2017;9(2):12.
4. Gilead Sciences, Inc. AmBisome (amphotericin B) liposome for injection [package insert]. Foster City (CA): Gilead Sciences, Inc.; 2012 Mar [cited 2025 Apr 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050740s021lbl.pdf
5. Talon Therapeutics, Inc. Marqibo (vincristine sulfate liposome injection) [package insert]. South San Francisco (CA): Talon Therapeutics, Inc.; 2012 Aug [cited 2025 Apr 17]. Available from:https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202497s000lbl.pdf
6. Alnylam Pharmaceuticals, Inc. ONPATTRO (patisiran) lipid complex injection [package insert]. Cambridge (MA): Alnylam Pharmaceuticals, Inc.; 2018 Aug [cited 2025 Apr 17]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/210922s000lbl.pdf
7. Pfizer Inc. BioNTech manufacturing GmbH. COMIRNATY (COVID-19 vaccine, mRNA) suspension for injection [package insert]. (New York) (NY): Pfizer Inc.; 2024 Aug [cited 2025 Apr 17]. Available from: https://www.fda.gov/media/151707/download
8. ModernaTX, Inc. SPIKEVAX (COVID-19 vaccine, mRNA) suspension for injection [package insert]. Cambridge (MA): ModernaTX, Inc.; 2025 Jan [cited 2025 Apr 17]. Available from: https://www.fda.gov/media/155675/download
9. Mathieu E, Ritchie H, Ortiz-Ospina E, et al. A global database of COVID-19 vaccinations. Nat Hum Behav. 2021;5(7):947–953.
10. Semple SC, Mui BL, Tam YK, et al. Cationic lipids and methods for nucleic acid delivery. World Intellect Property Organ. 2005 Dec 22.WO2005120152A1.
11. Aldosari BN, Alfagih IM, Almurshedi AS. Lipid nanoparticles as delivery systems for RNA-based vaccines. Pharmaceutics. 2021;13(2):206.
12. Mehta M, Bui TA, Yang X, et al. Lipid-based nanoparticles for drug/gene delivery: an overview of the production techniques and difficulties encountered in their industrial development. ACS Mater Au. 2023;3(6):600–619.
13. Fisher AC, Anderson K, Aldridge B, et al. An audit of pharmaceutical continuous manufacturing regulatory submissions and outcomes in the US. Int J Pharm. 2022;622:121778.
14. Panzitta F, Della Ventura B, Caputo D, et al. The strategic relevance of manufacturing technology: an overall quality concept to promote innovation preventing drug shortage. Int J Pharm. 2017;516(1–2):144–157.
15. Lee SL, O’Connor TF, Yang X, et al. Modernizing pharmaceutical manufacturing: from batch to continuous production. J Pharm Innov. 2015;10(3):191–199.
16. Evers MJW, Kulkarni JA, van der Meel R, et al. State-of-the-art design and rapid-mixing production techniques of lipid nanoparticles for nucleic acid delivery. Small Methods. 2018;2(9):1700375.doi: 10.1002/smtd.201700375
17. Lopes C, Fernandes E, Baptista PV, et al. Microfluidic production of mRNA-loaded lipid nanoparticles for vaccine applications. Expert Opin Drug Deliv. 2022;19(10):1381–1395.
18. Costa AP, Xu X, Khan MA, et al. Liposome formation using a coaxial turbulent jet in co-flow. Pharm Res. 2016;33(2):404–416.
19. Yenduri G, Costa AP, Xu X, et al. Impact of critical process parameters and critical material attributes on the critical quality attributes of liposomal formulations prepared using continuous processing. Int J Pharm. 2022;619:121700. doi: 10.1016/j.ijpharm.2022.121700
20. Laramy Mn O, Costa AP, Xu X, et al. Process robustness in lipid nanoparticle production: a comparison of microfluidic and turbulent jet mixing. Mol Pharm. 2023;20(8):4285–4296. doi: 10.1021/acs.molpharmaceut.3c00390
21. Costa AP, Jornitz MW. The new continuous and controlled approach to nanoparticle processing. Bioprocess Int. 2024 Nov 14.
22. Rodríguez V, Blanco E, Choi J, et al. Nano-based approved pharmaceuticals for cancer treatment: present and future challenges. Biomolecules. 2022;12(6):784. doi: 10.3390/biom12060784
23. Shemesh CS, Momin N, Kandalaft LE, et al. Personalized cancer vaccines: clinical landscape, challenges, and opportunities. Mol Ther. 2021;29(2):555–570. doi: 10.1016/j.ymthe.2020.09.038
24. Tenchov R, Bird R, Curtze AE, et al. Lipid nanoparticles—from liposomes to mRNA vaccine delivery, a landscape of research diversity and advancement. ACS Nano. 2021;15(11):16982–17015.
25. Rawlings B, Pora H. Environmental impact of single-use and reusable bioprocess systems. Bioprocess Int. 2009;7(2):18–26.
26. Song CH, Han JW. Patent cliff and strategic switch: exploring strategic design possibilities in the pharmaceutical industry. Springerplus. 2016;5(1):692.
27. Cullis PR, Felgner PL. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov. 2024;23(9):709–722.
28. Smolack H, Calatayud A. Pharma companies turn to AI to speed up drug development, but hit hurdles. Wall Str J. 2025 Feb 10.
29. US Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. ICH Q13: continuous manufacturing of drug substances and drug products: guidance for industry. 2023 Mar.
30. O’Brien Laramy M, Costa AP, Xu X, et al. Chemistry, manufacturing and controls strategies for using novel excipients in lipid nanoparticles. Nat Nanotechnol. 2025;20(3):331–344.
✦
关于我们
江苏百奥信康医药科技有限公司是一家以新药研发驱动制药全产业链发展的高科技创新型医药企业，也是国家高新技术企业、江苏省专精特新企业。百奥信康聚焦改良型新药，已构建纳米胶束、人工智能及转录组大数据两大核心技术平台。百奥信康以研发自我持有的改良型新药为主业，同时为国内外客户提供改良型新药研发服务。
百奥信康致力于做中国最成功的改良型新药！
版权及免责声明
「百奥信康」公众号推送的内容来源于原创或根据公开资料整理编辑，欢迎个人转发至朋友圈。媒体或机构如需转载，请完整注明：（1）本文转载自百奥信康公众号（ID: BioScenePharma）；（2）作者栏请填写：百奥信康；（3）插入百奥信康公众号链接。
本公众号的目的在于分享行业相关知识、传递最新医药资讯。如有侵权，请在留言栏及时告知，我们将及时删除相关信息。本公众号推送的文章中的观点不代表百奥信康的立场，也不是治疗方案的推荐。如需获得诊断或治疗方面的指导，请前往正规医院就诊。
2026-05-13
International Journal of Antimicrobial Agents Volume 67, Issue 1
国际抗微生物制剂杂志 67卷 1期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/1
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会新闻与信息页）
1
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与信息页
Article 107688
Antimicrobial Pharmacometrics（抗菌药物药代动力学）
2
Model-informed precision pyrazinamide dosing: The establishment of a population pharmacokinetic model repository for clinical decision support
基于模型的精准吡嗪酰胺剂量调整：建立用于临床决策支持的人群药代动力学模型库
Huan Zhang, Lu Han, Xiao-Qin Liu, Juan Wang, ... Zheng Jiao
Article 107658
Global Landscape of Phage Therapy（噬菌体治疗的全球概况）
3
Nanomedicine for phage therapy: Encapsulation strategies for enhanced antimicrobial efficacy
噬菌体治疗的纳米医学：增强抗菌功效的封装策略
Alexis Dorta-Gorrín, Verónica Salgueiriño, Lorena García-Hevia
Article 107660
4
Antibiotic-mediated prophage activation: Mechanisms, consequences, and therapeutic implications
抗生素介导的原噬菌体激活：机制、后果及治疗意义
Damir Gavric, Petar Knezevic
Article 107655
5
Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol – A prospective feasibility and proof of concept study in the Brazilian context
噬菌体治疗高风险患者中产KPC肺炎克雷伯菌的定植清除：KIDNAP研究方案——巴西背景下的一项前瞻性可行性及概念验证研究
Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C. Gales
Article 107673
AI strategies to combat AMR（人工智能对抗抗菌药物耐药性的策略）
6
Development and validation of machine learning models to predict vancomycin- and teicoplanin-associated acute kidney injury: A retrospective, multicenter study
开发和验证机器学习模型用以预测万古霉素和替考拉宁相关的急性肾损伤：一项回顾性、多中心研究
Pin-Yi Lo, Fan-Ying Chan, Yi-En Ku, San-Yuan Wang, Hsiang-Yin Chen
Article 107651
Reviews（综述）
7
A systematic review and meta-analysis of the global epidemiology of carbapenem-resistant Escherichia coli
碳青霉烯耐药大肠埃希菌全球流行病学的系统综述和荟萃分析
Mikaela M. Walker, Jason A. Roberts, Yixuan Li, Fekade B. Sime
Article 107668
8
Molecular mechanisms of resistance and tolerance of Staphylococcus aureus to daptomycin
金黄色葡萄球菌对达托霉素耐药和耐受的分子机制
Candice Lim, Geoffrey W. Coombs, Shakeel Mowlaboccus
Article 107678
Full Length Articles（长篇论著）
9
Antimicrobial peptide CATH-1 combats Streptococcus suis by targeting serine/threonine kinase
抗菌肽CATH-1通过靶向丝氨酸/苏氨酸激酶对抗猪链球菌
Yi Lu, Xiaoying Yu, Yandi Pan, Hang Yin, ... Rendong Fang
Article 107656
10
The antiarrhythmic drugs dronedarone and amiodarone exhibit potent in vitro and in vivo activity against Clostridioides difficile
抗心律失常药物决奈达隆和胺碘酮对艰难梭菌表现出强效的体内外活性
Ahmed A. Abouelkhair, Nader S. Abutaleb, Mohamed N. Seleem
Article 107649
11
Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Türkiye: A multi-centre retrospective matched-cohort study
头孢他啶-阿维巴坦与土耳其其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究
Abdullah Tarık Aslan, Elif Seren Tanriverdi, Sibel Yıldız Kaya, Gozde Dalgan, ... Murat Akova
Article 107650
12
An easy-to-use predictive score for identifying patients at risk of suboptimal linezolid exposure and candidates for therapeutic drug monitoring
一种易于使用的预测评分，用于识别存在利奈唑胺暴露不足风险及需进行治疗药物监测的患者
Daniel Fresán, Luisa Sorlí, Jaume Barceló-Vidal, Ana Rodrigo-Moreno, ... Sonia Luque
Article 107661
13
Urinary exosome-derived microRNAs as biomarkers of tenofovir disoproxil fumarate (TDF)-induced renal toxicity in people with HIV-1
尿液外泌体衍生的微小RNA作为HIV-1感染者使用富马酸替诺福韦二吡呋酯（TDF）引起肾毒性的生物标志物
José L. Casado, Pilar Vizcarra, Francisco J. Hernández-Walias, José Manuel del Rey, ... Alejandro Vallejo
Article 107654
14
Global genomic epidemiology of carbapenemase-producing Klebsiella pneumoniae, 1996–2023
1996-2023年产碳青霉烯酶肺炎克雷伯菌的全球基因组流行病学
Yuxia Shi, Dongxiao Ru, Minge Wang, Shengliang Cao, ... Jianbiao Lu
Article 107657
15
Two Tail Protein-Derived Capsule Depolymerases From Phage vB_KpnS_GH-K1 are Effective Against Pneumonia Caused by K2 Serotype Klebsiella pneumoniae
来自噬菌体vB_KpnS_GH-K1的两种尾蛋白衍生的荚膜多糖解聚酶对K2血清型肺炎克雷伯菌引起的肺炎有效
Guiyang Ge, Hongbei Ge, Jianhui Xu, Bing Yue, ... Rui Du
Article 107662
16
Discrepancy between WGS-based genotypic and phenotypic drug susceptibility testing of first and second-line drugs for Mycobacterium tuberculosis: Limited impact of unknown resistance mechanisms
结核分枝杆菌一线和二线药物基于全基因组测序的基因型与表型药物敏感性测试之间的差异：未知耐药机制的影响有限
Ruimin Hong, Peng Xu, Wenjie Lai, Chi Wu, ... Qian Gao
Article 107666
17
Consumption and expenditure on fidaxomicin and oral vancomycin for Clostridioides difficile infection: A 12-year longitudinal study of 43 countries and regions
43个国家和地区12年艰难梭菌感染使用菲达霉素和口服万古霉素的消费和支出情况纵向研究
Yin Zhang, Xue Li, Angel Y.S. Wong, Vincent K.C. Yan, ... Wai K. Leung
Article 107664
18
Genome-wide insight into the evolution and global transmission of tigecycline resistant tet(X4)-carrying Klebsiella species across reservoirs
全基因组视角下携带耐替加环素tet(X4)的克雷伯菌属在各储存库中的进化与全球传播
Yuye Wu, Yawen Yu, Xueqian He, Weifang Mao, ... Zhi Ruan
Article 107665
19
Combined disk-based tests for phenotypic identification of KPC variants in Enterobacterales
基于联合药敏试验的肠杆菌目中KPC变异体的表型鉴定
Feng Yang, Li Ding, Siquan Shen, Chengkang Tang, ... Fupin Hu
Article 107663
20
Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database
抗菌药物耐药性措施的实施及新冠疫情的出现对日本全民抗菌药物使用的影响：一项使用国家索赔数据库的回顾性队列研究
Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari
Article 107667
21
Ceftazidime-avibactam resistance among clinical isolates of Citrobacter freundii, Morganella morganii, Providencia spp. and Serratia marcescens across five continents: Data from the Antimicrobial Testing Leadership and Surveillance (ATLAS) programme, 2016–2023
2016-2023年抗菌药物测试领导与监测（ATLAS）项目数据：五大洲弗氏柠檬酸杆菌、摩氏摩根菌、普罗维登斯菌属和产气肠杆菌临床分离株对头孢他啶-阿维巴坦的耐药性
Hao-En Jan, Jiun-Ling Wang, Nan-Yao Lee, Shun-Chung Hsueh, ... Po-Ren Hsueh
Article 107669
22
Impact of DNA-stored mutations on virological response in virologically suppressed PWH in the switch to modern regimens
DNA储存突变对病毒抑制的HIV感染者转换至现今治疗方案时病毒学反应的影响
Francesca Lombardi, Elio Gentilini Cacciola, Federica Carli, Francesco Saladini, ... Maria Mercedes Santoro
Article 107670
23
NucS Thr74Ile confers mutator phenotype in a globally disseminated clinical Mycobacterium abscessus subsp. abscessus clone
NucS Thr74Ile在全球传播的临床脓肿分枝杆菌脓肿亚种克隆中赋予突变表型
Juan Li, Junsheng Fan, Zhili Tan, Anqi Li, ... Haiqing Chu
Article 107677
24
Adverse effects of posaconazole on adrenal steroid biosynthesis: An integrative approach using FAERS-based pharmacovigilance and systematic review with meta-analysis of randomised controlled trials
泊沙康唑对肾上腺类固醇生物合成的不良影响：基于FAERS的药物警戒和随机对照试验系统综述与荟萃分析的综合方法
Yuki Nakano, Kazumasa Kotake, Yuki Asai, Masayuki Murata, ... Hirotsugu Hasuwa
Article 107676
25
SU3327: A multi-target compound targeting bacterial menaquinone and DNA
SU3327：一种靶向细菌甲基萘醌和DNA的多靶点化合物
Shuge Wang, Ke Zhao, Ziqi Chen, Chengtao Sun, ... Dejun Liu
Article 107679
26
blaKPC-2 amplification and a novel mrcA mutation drive Cefiderocol heteroresistance in ST11 CRKP
blaKPC-2扩增和一种新型mrcA突变驱动ST11碳青霉烯耐药肺炎克雷伯菌对头孢地尔的异质性耐药
Yuxuan Liu, Hanxu Hong, QianBin Dai, Linping Fan, ... Yang Liu
Article 107682
27
P1-like phage-plasmids drive blaCTX-M-27 transmission through lysogenic conversion and transposition
P1样噬菌体质粒通过溶原性转换和转座驱动blaCTX-M-27传播
Zengfeng Zhang, Chunlei Shi
Article 107686
28
Streptomyces taklimakanensis sp. nov. TRM43335 produces 3-indole carbaldehyde a promising inhibitor of carbapenem-resistant Acinetobacter baumannii: In vitro and in vivo evaluation
塔克拉玛干沙漠放线菌新种Streptomyces taklimakanensis sp. nov. TRM43335产生3-吲哚甲醛——一种有前景的碳青霉烯耐药鲍曼不动杆菌抑制剂：体内外评估
Yanchun Qin, Wen ting Zhou, Ling Wang, Shengqiang Yang, ... Hong Zeng
Article 107685
Short Communications（短篇通讯）
29
Fluconazole exposure during mechanical circulatory support (MCS) device insertion
机械循环支持（MCS）装置植入期间的氟康唑暴露
Kelly A. Cairns, Kate Morton, Trisha N. Peel, Iain J. Abbott, ... Michael J. Dooley
Article 107647
30
Evaluation of sulbactam-durlobactam disk diffusion and broth microdilution methods for Acinetobacter baumannii
评估磺苄西林-杜洛巴坦对鲍曼不动杆菌的纸片扩散法和肉汤微量稀释法
Xiaolan Hong, Xinying Wang, Xin Xiang, Siquan Shen, ... Yan Guo
Article 107659
Letters to the Editor（读者来信）
31
Comment on “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study”
对“土耳其头孢他啶-阿维巴坦与其他适当抗菌疗法治疗产OXA-48或KPC的肠杆菌目感染的比较：一项多中心回顾性匹配队列研究”的评论
S. Dhanya Dedeepya, Vaishali Goel, Nivedita Nikhil Desai
Article 107671
32
Emergence of TMexCD-TOprJ-producing Vibrio furnissii in retail shellfish
零售贝类中出现产TMexCD-TOprJ的弗尼斯弧菌
Haotian Deng, Zhongpeng Cai, Kexin Li, Ludan Xiao, ... Shaowen Li
Article 107680
International Journal of Antimicrobial Agents Volume 67, Issue 2
国际抗微生物制剂杂志 67卷 2期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/2
1
Title Page & Editorial Board
标题页与编委会
Article 107727
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息页）
2
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与信息页
Article 107719
Systematic Reviews and Meta-analyses（系统综述与荟萃分析）
3
Ceftazidime/avibactam and ceftolozane/tazobactam for severe paediatric infections: A systematic review, meta-analysis, and evidence map
头孢他啶/阿维巴坦与头孢洛扎/他唑巴坦治疗儿童重症感染：一项系统评价、荟萃分析及证据图谱研究
Paula Pimenta-de-Souza, Alice Ramos-Silva, Valcieny Sandes, Patrícia Portella, ... Elisangela Costa Lima
Article 107710
Full Length Articles（长篇论著）
4
Downregulation of an NfsA-like nitroreductase causes metronidazole resistance in Gardnerella vaginalis
NfsA样硝基还原酶下调可导致阴道加德纳菌对甲硝唑耐药
Ana Paunkov, Anna-Lena Mayr, Vera Oberbauer, Timo Schwebs, ... David Leitsch
Article 107681
5
Machine–learning and gene–synergy networks reveal interpretable drivers of antibiotic resistance in Staphylococcus aureus
机器学习与基因协同网络揭示金黄色葡萄球菌抗生素耐药性的可解释驱动因素
Jie Xu, Yuan Li, Ying Wang, Fang Liu, ... Haiyan Yang
Article 107690
6
Enhanced molecular surveillance for gonococcal resistance during doxycycline post-exposure prophylaxis implementation
在实施多西环素暴露后预防措施期间加强对淋球菌耐药的分子监测
Ziyuan Zhao, Leshan Xiu, Junping Peng
Article 107689
7
Fosfomycin-based combinations against carbapenemase-producing Klebsiella pneumoniae bloodstream infections: Correlating in vitro synergy with clinical outcomes
以磷霉素为基础的联合用药治疗产碳青霉烯酶肺炎克雷伯菌血流感染：体外协同作用与临床预后的相关性
Melike Törüyenler Coşkunpınar, Güle Çınar, Duygu Öcal, İsmail Balık
Article 107687
8
EnvZ mutation–driven downregulation of catecholate siderophore receptors and concurrent TonB complex repression confer cefiderocol resistance in a KPC-producing ST11-KL64 hypervirulent Klebsiella pneumoniae
EnvZ突变驱动儿茶酚酸铁载体受体下调表达，同时抑制TonB复合体，使产KPC酶的ST11-KL64型高毒力肺炎克雷伯菌对头孢地尔产生耐药性
Danni Pu, Xianxia Zhuo, Rongrong Song, Chunhui Wang, ... Bin Cao
Article 107693
9
Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis
治疗肾盂肾炎和复杂性尿路感染的抗生素类别比较：一项系统综述和荟萃分析
Digbijay Kunwar, Itay Zahavi, Judit Olchowski, Hagar Dallasheh, Mical Paul
Article 107696
10
Enhancing meropenem therapy in critical care: A retrospective study of PK/PD target attainment and therapeutic drug monitoring
强化重症监护病房中美罗培南的治疗：一项关于药代动力学/药效学目标达成情况及治疗药物监测的回顾性研究
Jingli Liao, Chao Li, Jingxian Liu, Wei Wu, ... Lixia Li
Article 107697
11
Zinc deficiency reverses biofilm azole resistance in Candida albicans
锌缺乏可逆转白色念珠菌生物膜对唑类药物的耐药性
Yingzhe Wang, Shigan Ye, Yuan Deng, Yingting Huang, Xiaoliang Zhu
Article 107695
12
Development of ceftazidime–avibactam resistance driven by conversion of blaKPC-2 to blaKPC-78 during treatment of ST463 carbapenem-resistant Pseudomonas aeruginosa infection
治疗ST463型碳青霉烯类耐药铜绿假单胞菌感染过程中，因blaKPC-2基因突变为blaKPC-78基因而引发的头孢他啶-阿维巴坦耐药性的产生
Haotian Xu, Tingjuan Zhang, Xueying Cui, Jingyi Guo, ... Xi Li
Article 107703
13
ATP-binding cassette transporters mediate and regulate metronidazole resistance in Clostridioides difficile
ATP结合盒转运蛋白介导并调控艰难梭菌对甲硝唑的耐药性
Teng Xu, Ying Zhou, Qingqing Xu, Li Wang, ... Haihui Huang
Article 107709
14
Regorafenib, a multitargeted kinase inhibitor, inhibits enterovirus 71 infection by suppressing the MAPK pathway
瑞戈非尼（Regorafenib）作为一种多靶点激酶抑制剂，可通过抑制丝裂原活化蛋白激酶（MAPK）通路来抑制肠道病毒71型感染
Xinyu Zhang, Yuanyuan Cao, Yu Liu, Shengqun Deng, ... Qi Tang
Article 107711
Short Communications（短篇通讯）
15
Effect of ibuprofen on the pharmacokinetics of intravenous flucloxacillin in healthy adults
布洛芬对健康成年人静脉注射氟氯西林药代动力学的影响
Alison Boast, Amy Legg, James McCarthy, Jason A Roberts, ... Amanda Gwee
Article 107684
16
Formation of a novel multiresistance plasmid co-carrying tigecycline, carbapenem, and other resistance genes by recombination during conjugative transfer in Klebsiella pneumoniae
肺炎克雷伯菌在接合转移过程中通过重组形成一种共携带替加环素、碳青霉烯类及其他耐药基因的新型多重耐药质粒
Runhao Yu, Zhong Chen, Stefan Schwarz, Hong Yao, ... Xiang-Dang Du
Article 107683
17
Vancomycin clearance compared to creatinine clearance by timed urine collection in the intensive care unit
重症监护室中通过定时尿液收集法比较万古霉素清除率与肌酐清除率
Andrew Chantha Hean, Rinoj Mathew, Frank Chu, Linda Awdishu
Article 107704
18
Risk of infective endocarditis in oncohaematological patients undergoing active treatment with Enterococcus faecalis bloodstream infection: A retrospective multicentre study
接受积极治疗的血液肿瘤患者合并屎肠球菌（Enterococcus faecalis）血流感染时发生感染性心内膜炎的风险：一项回顾性多中心研究
Miguel Ángel Consuegra Pérez, Sara Grillo, Alexander Rombauts, María Alba Rivera Martínez, ... Laura Escolà-Vergé
Article 107706
Letters to the Editor（致编辑的信）
19
In reply to the letter to editor regarding “Comparison of ceftazidime-avibactam with other appropriate antimicrobial therapy for the treatment of OXA-48- or KPC-producing Enterobacterales infections in Turkiye: A multi-centre retrospective matched-cohort study”
针对就《土耳其头孢他啶-阿维巴坦与其他适宜抗菌疗法治疗产OXA-48或KPC肠杆菌科感染的对比：一项多中心回顾性匹配队列研究》一文致编辑的信的回复
Abdullah T. Aslan, Patrick N.A. Harris, David L. Paterson
Article 107691
20
Aztreonam–avibactam pharmacokinetics during extracorporeal membrane oxygenation support: First insights from a case report
体外膜肺氧合支持期间氨曲南-阿维巴坦的药代动力学特征：首例病例报告的初步见解
Alba Pau-Parra, Sònia Luque, Laura Doménech, María Martínez-Pla, ... Jordi Riera
Article 107692
21
Comments on ‘Acute kidney injury associated with colistin sulphate vs. polymyxin B sulphate therapy: A real-world, retrospective cohort study’
对“硫酸黏菌素与硫酸多黏菌素B治疗相关急性肾损伤：一项真实世界回顾性队列研究”的评论
Genzhu Wang
Article 107702
22
Superintegron of Vibrio paracholerae as a reservoir of antibiotic resistance genes
副霍乱弧菌（或拟霍乱弧菌）超级整合子作为抗生素耐药基因的储存库
Sergio Mascarenhas Morgado, Erica Lourenço da Fonseca, Ana Carolina Paulo Vicente
Article 107708
23
Clinical outcomes of metronidazole dosing strategies in obese patients with Bacteroides bloodstream infections
肥胖患者脆弱拟杆菌（Bacteroides）血流感染时甲硝唑不同给药策略的临床疗效
Sunish Shah, Rachel V. Marini, Dayna McManus, Ryan K. Shields, ... Tyler Tate
Article 107701
Corrigendum（勘误表）
24
Corrigendum to “Impact of antimicrobial resistance measures and the emergence of COVID-19 on antimicrobial use throughout the Japanese population: A retrospective cohort study using a national claims database” [International Journal of Antimicrobial Agents Volume 67(2026)107667]
对《抗菌药物耐药性评估及新冠疫情的爆发对日本全民抗菌药物使用情况的影响：一项基于国家医保理赔数据库的回顾性队列研究》[《国际抗微生物制剂杂志》第67卷（2026年）第107667篇]的勘误说明
Ryuji Koizumi, Shinya Tsuzuki, Yusuke Asai, Kensuke Aoyagi, Norio Ohmagari
Article 107694
International Journal of Antimicrobial Agents Volume 67, Issue 3
国际抗微生物制剂杂志 67卷3期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/3
1
Title Page & Editorial Board
目录与编委会
Article 107753
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页面）
2
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与资讯页面
Article 107746
Hot Topic（热点）
3
Artificial intelligence and machine learning in antimicrobial discovery, resistance prediction, and precision therapy
人工智能与机器学习在抗菌药物发现、耐药性预测及精准治疗中的应用
Reema Singh, Yu-Wei Lin, Jinxin Zhao, Jian Li
Article 107715
Reviews（综述）
4
Pharmacokinetics and pharmacodynamics of bacteriophage therapy: A scoping review
噬菌体治疗的药代动力学和药效学：一项范围综述
Andrew T Nguyen, Nicita Mehta, KaiLan Mackey, Thomas Cummiskey, ... Jason Young
Article 107705
5
Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review
益生菌菌株、疗程及剂量对预防重症监护病房（ICU）获得性感染的影响：一项范围综述
Aqdar Mufareh Al-Aklabi, Sara Muteb Alotaishan, Yasmin Youssuf Al-Gindan, Rabie Yousif Khattab
Article 107714
Full Length Articles（完整论著）
6
Pharmacokinetics of ampicillin, sulbactam and combined ampicillin/sulbactam in subcutis, muscle and plasma: A microdialysis trial in healthy volunteers
氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下、肌肉和血浆中的药代动力学：一项健康志愿者微透析试验
Anselm Jorda, Lena Pracher, Marlene Prager, Felix Bergmann, ... Valentin al Jalali
Article 107716
7
Beneficial effects of a compound probiotic in Helicobacter pylori-infected patients aged over 40 years: An open-label randomised clinical trial
复合益生菌对40岁以上幽门螺杆菌感染患者的有益作用：一项开放标签随机临床试验
Chenghai Yang, Jie Cheng, Meng Zhang, Bingyun Lu, ... Ye Chen
Article 107712
8
Skin pharmacokinetics and pharmacodynamics in patients with post-kala-azar dermal leishmaniasis
内脏利什曼病（黑热病）后皮肤利什曼原虫病患者的皮肤药代动力学与药效学
Wan-Yu Chu, Om Prakash Singh, Shyam Sundar, Krishna Pandey, ... Thomas P. C Dorlo
Article 107713
9
Amodiaquine hydrochloride facilitates mycobacterial clearance via triggering autophagy in macrophages
盐酸阿莫地喹通过触发巨噬细胞自噬促进分枝杆菌清除
Hongxuan Yan, Jinfeng Yuan, Shujuan Duan, Fuzhen Zhang, ... Mengqiu Gao
Article 107720
Short Communications（短篇通讯）
10
Risk factors for bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii in ICU patients with any site colonisation: a prospective observational study
重症监护病房（ICU）患者任何部位定植碳青霉烯耐药鲍曼不动杆菌造成血流感染的危险因素：一项前瞻性观察研究
Giusy Tiseo, Valentina Galfo, Aurelio Lepore, Manuela Pogliaghi, ... Marco Falcone
Article 107717
11
Resistance to sulbactam/durlobactam in carbapenem-resistant Acinetobacter baumannii in treatment-naive setting: in vitro data and genomic insights from Italian bloodstream isolates
初次用药背景下耐碳青霉烯鲍曼不动杆菌对舒巴坦/杜洛巴坦的耐药性：来自意大利血流感染分离株的体外数据及基因组见解
Gabriele Bianco, Gherard Batisti Biffignandi, Matteo Boattini, Sara Comini, ... Paolo Gaibani
Article 107718
12
Real-world daptomycin use with a focus on muscle toxicity: A multicentric retrospective study
聚焦肌肉毒性的达托霉素实际使用情况：一项多中心回顾性研究
C. Airaud, E. Demay, V. Dias Meireles, D. Luque Paz, ... A. Bacle
Article 107721
International Journal of Antimicrobial Agents Volume 67, Issue 4
国际抗微生物制剂杂志 67卷4期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/4
1
Title Page & Editorial Board
目录与编者按
Article 107775
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与信息）
2
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与信息
Article 107765
Hot Topic（热点）
3
Phage therapy in China: Arming the One Health approach
中国噬菌体疗法：助力“同一健康”策略实施
Na Li, Qimao Yang, Bijie Hu, Tongyu Zhu, Nannan Wu
Article 107731
Global Landscape of Phage Therapy（噬菌体疗法的全球概况）
4
CRISPR/Cas9-engineered Salmonella phage displaying antimicrobial peptide LL37 for enhanced antibacterial activity
利用CRISPR/Cas9技术改造的沙门氏菌噬菌体，展示出抗菌肽LL37，用以增强抗菌活性
Su Jin Jo, Se Chang Park, Sang Guen Kim
Article 107734
5
Phage resistance bidirectionally altered antibiotic susceptibility in Klebsiella pneumoniae via galE mutation
噬菌体抗性通过galE基因突变双向改变肺炎克雷伯菌的抗生素敏感性
Braira Wahid, Sue C. Nang, Jinxin Zhao, Zhi Ying Kho, ... Jian Li
Article 107738
Reviews（综述）
6
Resistance of uropathogens to gepotidacin: A systematic review of in vitro antimicrobial susceptibility studies
尿路病原体对吉培西林（gepotidacin，一种新型抗菌药）的耐药性：体外抗菌敏感性研究的系统综述
Matthew E. Falagas, Laura T. Romanos, Eleni D. Katritsi, Iva D. Tzvetanova
Article 107723
Full Length Articles（完整论著）
7
Identification of KPC-271, a novel KPC variant conferring ceftazidime-avibactam resistance while restoring carbapenem susceptibility in ST15-KL19 Klebsiella pneumoniae
新型KPC变体KPC-271的鉴定：该变体使ST15-KL19型肺炎克雷伯菌对头孢他啶-阿维巴坦产生耐药性，同时恢复其对碳青霉烯类的敏感性
Hongjian Ou, Siquan Shen, Chengkang Tang, Weiwei Yang, ... Fupin Hu
Article 107725
8
Rapid detection of NDM-producing carbapenem-resistant Escherichia coli using MALDI-TOF MS combined with machine learning techniques
基质辅助激光解吸电离飞行时间质谱（MALDI-TOF MS）结合机器学习技术快速检测产新德里金属β-内酰胺酶（NDM）的碳青霉烯类耐药大肠杆菌
Rongrong Dong, Yifei Wang, Lei Song, Jiayin Wang, ... Jiancheng Xu
Article 107726
9
Global distribution and genomic architectures of plasmid-mediated quinolone resistance genes in Shigella from 1998 to 2025
1998年至2025年志贺氏菌中质粒介导的喹诺酮类耐药基因的全球分布及基因组结构特征
Juan Geng, Cheng Cheng, Xu Liu, Jinzhao Long, ... Guangcai Duan
Article 107737
Short Communications（快报）
10
Global epidemiological trend of Klebsiella pneumoniae ST23: Emergence of KL57 lineage carrying dual carbapenemases
肺炎克雷伯菌ST23型全球流行病学趋势：携带双碳青霉烯酶的KL57谱系的出现
Shuangshuang Li, Guoli Li, Xueqian He, Yawen Yu, ... Zhi Ruan
Article 107722
11
Antibiotic susceptibility of Gram-negative bacteria in cerebrospinal fluid compared with Mueller-Hinton broth and artificial cerebrospinal fluid
脑脊液中革兰氏阴性菌对Mueller-Hinton肉汤和人工脑脊液的抗生素敏感性比较
Katrin Biesner, Marija Djukic, Utz Reichard, Roland Nau, Jana Seele
Article 107730
Letters to the Editor（致编辑的信）
12
Global, regional, and national burden of multidrug-resistant organisms, 1990–2021
1990 - 2021年全球、区域及国家层面多重耐药菌的疾病负担
Lian Liu, Hong Luo
Article 107724
13
Beyond categorical agreement: Antibiotic-specific time to result in rapid susceptibility testing from Gram-negative positive blood cultures
超越分类一致性：针对革兰氏阴性菌血培养阳性的快速药敏试验中不同抗生素的结果检出时间
Tiziana D’Inzeo, Damiano Squitieri, Cataldo Maria Mannavola, Matteo Zelinotti, ... Brunella Posteraro
Article 107735
14
Comment on “Phage therapy for KPC-producing Klebsiella pneumoniae de colonisation in high-risk patients: The KIDNAP Study Protocol”
对“针对高危患者中产KPC肺炎克雷伯菌定植的噬菌体疗法：KIDNAP研究方案”的评论
Yinjia Lou, Yiqing Han
Article 107733
International Journal of Antimicrobial Agents Volume 67, Issue 5
国际抗微生物制剂杂志 67卷5期
https://www.sciencedirect.com/journal/international-journal-of-antimicrobial-agents/vol/67/issue/5
1
Title Page & Editorial Board
目录及编委会
Article 107819
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page（国际抗菌化疗学会（ISAC）新闻与资讯页）
2
International Society of Antimicrobial Chemotherapy (ISAC) News and Information Page
国际抗菌化疗学会（ISAC）新闻与资讯页
Article 107803
Editor's Choice（编辑精选）
3
cirA promoter disruption and SHV-12 production contribute to cefiderocol resistance in carbapenem-resistant Klebsiella pneumoniae
cirA启动子破坏与SHV-12酶的产生共同导致碳青霉烯耐药肺炎克雷伯菌对头孢地尔产生耐药性
Fang Shen, Xiaochen Liu, Tailong Lei, Jingjing Quan, ... Qiucheng Shi
Article 107756
Hot Topic（热点）
4
Formulating and stabilising therapeutic phages: A review
治疗性噬菌体的配制与稳定化：综述
Eleni Siafakas, Hien T.T. Duong, Jonathan R. Iredell
Article 107759
Global Landscape of Phage Therapy（噬菌体疗法的全球概况）
5
Assessing carbonylation in Pseudomonas aeruginosa clinical isolates infected by bacteriophages using flow cytometry
利用流式细胞术评估受噬菌体感染的铜绿假单胞菌临床分离株中的羰基化情况
Jia Hao Yeo, Shuhua Thong, Shimin Jasmine Chung, Andrea Lay-Hoon Kwa
Article 107739
AI strategies to combat AMR（应对抗菌药物耐药性的人工智能策略）
6
Causality-informed models for multidrug-resistant organism prediction: Enabling effective ICU antibiotic stewardship
基于因果关系建模的多重耐药菌预测模型：助力重症监护室（ICU）有效开展抗生素管理
Linna Wang, Xinyu Guo, Yimin Chen, Siying Li, ... Li Lu
Article 107767
Reviews（综述）
7
Tissue pharmacokinetics of antifungal drugs: a review
抗真菌药物的组织药代动力学：综述
Felix Bergmann, Marlene Prager, Lena Pracher, Anselm Jorda, ... Markus Zeitlinger
Article 107743
8
New-generation antibiotics and nonantibiotic strategies against carbapenemase-producing Enterobacterales: More focus on metallo-β-lactamase producers
新一代抗生素及非抗生素策略针对产碳青霉烯酶肠杆菌科细菌：更聚焦于产金属β-内酰胺酶菌种
Shio-Shin Jean, Chih-Cheng Lai, Hou-Tai Chang, Hui-Che Hsiao, ... Po-Ren Hsueh
Article 107750
9
A window into resistance: The MEGA-plate as a model of evolutionary dynamics
洞见耐药性：MEGA 培养皿——一种模拟进化动态的模型
Maytham Hussein, Rafah Allobawi, James Barclay, Zhi Ying Kho, ... Tony Velkov
Article 107751
Full Length Articles（长篇论著）
10
Efficacy and safety of intracameral amphotericin B for fungal keratitis: A systematic review and meta-analysis
眼内注射两性霉素B治疗真菌性角膜炎的疗效与安全性：一项系统综述与荟萃分析
Kai-Yang Chen, Hoi-Chun Chan, Chi-Ming Chan
Article 107707
11
Urine NGAL adds to serum creatinine in predicting cefepime clearance in critically ill children at high risk of acute kidney injury
尿中性粒细胞明胶酶相关脂质运载蛋白（NGAL）联合血清肌酐，可更有效地预测急性肾损伤高风险危重症儿童头孢吡肟的清除率
Horace Rhodes Hambrick, Ronaldo Morales Junior, Calise Curry, Michaela Collins, ... Sonya Tang Girdwood
Article 107741
12
Integrative virtual and empirical screening to identify multi-target flavonoid quercetin-3-O-glucuronide for reducing MRSA pathogenicity
通过整合虚拟筛选与实证筛选，确定具有多靶点作用的黄酮类化合物槲皮素-3-O-葡萄糖醛酸苷可降低耐甲氧西林金黄色葡萄球菌（MRSA）的致病性
Hang Gao, Li Wang, Zeze Fu, Yun Sun, ... Yicheng Zhao
Article 107744
13
Validation of limited sampling strategies for polymyxin B therapeutic drug monitoring in critical care
重症监护中多粘菌素B治疗药物监测有限采样策略的验证
Yury A. Surovoy, Inna A. Galvidis, Akmal I. Alimov, Sergei V. Tsarenko, Maksim A. Burkin
Article 107740
14
Population pharmacokinetics of cefazolin and metronidazole in patients undergoing elective colorectal surgery
择期结直肠手术患者头孢唑林和甲硝唑的群体药代动力学研究
Rochelle Ryan, Scott McDonald, Steven C Wallis, Andre van Zundert, ... Jason A. Roberts
Article 107742
15
Omeprazole is associated with voriconazole-associated hepatotoxicity: PPI-stratified analysis and a clinically actionable nomogram from an 848-patient cohort
奥美拉唑与伏立康唑相关肝毒性有关：基于848例患者队列的质子泵抑制剂分层分析及临床可操作的列线图
Yuhang Ding, Yanhong Meng, Huaijun Zhu, Jinping Zhang, Qiuhui Wu
Article 107749
16
Treatment sequences of a phage and colistin combination trigger different evolution pathways of a multidrug-resistant Acinetobacter baumannii yielding distinct treatment outcomes
噬菌体与粘菌素（多粘菌素E）联合用药的不同治疗顺序可引发多重耐药鲍曼不动杆菌的不同进化路径，进而产生截然不同的治疗效果
Subhankar Mukhopadhyay, Xiaoxu Zhang, Kenneth K.W. To, Yannan Liu, ... Sharon S.Y. Leung
Article 107745
17
L-Cycloserine, not d-Cycloserine, inhibits IscS-mediated iron–sulfur cluster biosynthesis in Escherichia coli
L-环丝氨酸（而非D-环丝氨酸）抑制大肠杆菌中由IscS介导的铁硫簇生物合成
Lihe Zhang, Yongjuan Li, Yuhang Bao, Jie Feng, ... Wu Wang
Article 107761
18
Molecular mechanisms and clonal distribution of cefiderocol-resistant blaNDM-carrying Escherichia coli: A multi-centre study in China
携带产头孢他啶/阿维巴坦耐药基因blaNDM的大肠杆菌的分子机制及克隆分布：中国多中心研究
Chengkang Tang, Siquan Shen, Renru Han, Dandan Yin, ... Fupin Hu
Article 107762
Short Communications（短讯）
19
Present trajectories to forecasted future: A longitudinal analysis of hospital antibiotic use in China from 2013 to 2024 and projections to 2030
现状轨迹至预测未来：2013 年至 2024 年中国医院抗生素使用情况的纵向分析及至 2030 年的预测
Weibin Li, Fenqi Du, Ruowei Xiao, Weihsin Ko, ... Haishaerjiang Wushouer
Article 107764
Letters to the Editor（致编辑的信）
20
Comment on ‘Pharmacokinetics of ampicillin, sulbactam, and combined ampicillin/sulbactam in subcutis, muscle, and plasma: A microdialysis trial in healthy volunteers’
对“氨苄西林、舒巴坦及氨苄西林/舒巴坦联合用药在皮下组织、肌肉和血浆中的药代动力学：一项在健康志愿者中进行的微透析试验”的评论
Kishankumar Mahida, Snehal Rajendra Jagtap
Article 107736
21
Comment on: “Therapeutic drug monitoring of isavuconazole: Trends and update”
述评：“艾沙康唑治疗药物监测：趋势与最新进展”
Zhibin Xu, Shouning Zhou, Lulin Wang, Xiaohua Wang, ... Chunrong Ju
Article 107732
22
Comprehensive analysis of 16S rRNA methyltransferases in Enterobacterales isolated from dogs and cats reveals co-resistance with broad-spectrum β-lactamases
对从猫狗体内分离出的肠杆菌目细菌中16S rRNA甲基转移酶的全面分析揭示其与广谱β-内酰胺酶共存耐药性
Fábio Parra Sellera, Yawen Yu, Yingying Zhang, Luciana Sartori, ... João Pedro Rueda Furlan
Article 107747
23
Comment on "Effect of probiotic strain, duration, and dose on preventing ICU-acquired infection: A scoping review"
评论：“益生菌菌株、疗程和剂量对预防重症监护病房获得性感染的影响：一项范围综述”
Jiayi Yu
Article 107758
24
Comment on “Antibiotic class comparisons for the treatment of pyelonephritis and complicated urinary tract infections: A systematic review and meta-analysis”
对《肾盂肾炎及复杂性尿路感染治疗中不同类别抗生素的比较：一项系统综述与荟萃分析》一文的评论
Qiao Chen
Article 107770
Corrigendum（勘误表）
25
Corrigendum to “Phage therapy for KPC-producing Klebsiella pneumoniae decolonization in high-risk patients: The KIDNAP Study Protocol - A prospective feasibility and proof of concept study in the Brazilian context” [International Journal of Antimicrobial Agents Volume 67(2026)107673]
对“针对产KPC酶肺炎克雷伯菌定植清除的高危患者实施噬菌体治疗：《KIDNAP研究方案》——巴西背景下的一项前瞻性可行性及概念验证研究”[《国际抗微生物制剂杂志》第67卷（2026年）第107673篇]的勘误
Iris Najjar, Larissa Simão Gandolpho, Jôiciglecia Pereira dos Santos, Camila de Paula Siqueira, ... Ana C. Gales
Article 107766
2026-05-13
Journal of Antimicrobial Chemotherapy Volume 81, Issue 1抗菌化疗杂志81卷 1期
https://academic.oup.com/jac/issue
50th Anniversary Collection（50周年纪念合集）
Review（综述）
1
Artificial intelligence for improving decision-making in bacterial infection management: a narrative review
人工智能在改善细菌感染治疗决策中的应用：一项叙述性综述
Anisia Talianu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf470, https://doi.org/10.1093/jac/dkaf470
Reviews（综述）
2
Evolving landscape of methicillin-resistant Staphylococcus pseudintermedius: the emergence of new epidemic waves across Europe, Asia and North America
耐甲氧西林中间型葡萄球菌的演变格局：欧洲、亚洲和北美洲新流行浪潮的出现
Lillian Rose Giarratana and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf340, https://doi.org/10.1093/jac/dkaf340
3
Azithromycin resistance in non-typhoidal Salmonella: a review
非伤寒沙门氏菌对阿奇霉素的耐药性：综述
Zhe Zhu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf341, https://doi.org/10.1093/jac/dkaf341
4
Antibiotic pharmacodynamics: from MIC to advanced metrics and their applications
抗生素药效动力学：从最低抑菌浓度到高级指标及其应用
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf374, https://doi.org/10.1093/jac/dkaf374
5
Progress in the study of drug resistance mechanism of Bacillus cereus
蜡样芽孢杆菌耐药机制研究进展
Yuhang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf399, https://doi.org/10.1093/jac/dkaf399
6
The curious constraints on clofazimine
氯法齐明的奇特限制
Maple Goh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf430, https://doi.org/10.1093/jac/dkaf430
7
Antiplasmid systems: a novel strategy to combat antibiotic resistance
抗质粒系统：对抗抗生素耐药性的新策略
Mohd Asim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf472, https://doi.org/10.1093/jac/dkaf472
Systematic Review（系统综述）
8
Coccidioidomycosis in Europe: a systematic literature review of epidemiology, treatment and outcomes
欧洲球孢子菌病：流行病学、治疗和预后的系统文献综述
Priya Shastri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf407, https://doi.org/10.1093/jac/dkaf407
9
Systematic review of antimicrobial pharmacokinetic/pharmacodynamic indices in murine thigh and hollow fibre dose fractionation studies analysed with a standard method
用标准方法分析小鼠大腿和空心纤维剂量分次研究中的抗菌药物药代动力学/药效动力学指数的系统综述
Najla Alabdulkarim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf446, https://doi.org/10.1093/jac/dkaf446
Virtual Roundtable（虚拟圆桌会议）
10
Procalcitonin in the management of lower respiratory tract infection and sepsis
降钙素原在下呼吸道感染和败血症治疗中的应用
Ramy H Elshaboury and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf298, https://doi.org/10.1093/jac/dkaf298
Original Research（论著）
11
Model-based assessment of letermovir pharmacokinetics in allogeneic haematopoietic stem cell transplant recipients
来特莫韦在异基因造血干细胞移植受者中药代动力学的基于模型的评估
Chrisoula Tahtsidou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf427, https://doi.org/10.1093/jac/dkaf427
12
In vitro exebacase (CF-301) activity against methicillin-susceptible or methicillin-resistant Staphylococcus aureus and coagulase-negative staphylococci strains isolated from patients with infective endocarditis
体外试验评估依拉环素（CF-301）对甲氧西林敏感或甲氧西林耐药金黄色葡萄球菌及凝固酶阴性葡萄球菌（从感染性心内膜炎患者中分离）的活性
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf435, https://doi.org/10.1093/jac/dkaf435
13
Evaluation of subcutaneous amoxicillin/clavulanic acid pharmacokinetics as an alternative to the intravenous route in older patients—the PhASAge Study
评估皮下注射阿莫西林/克拉维酸药代动力学作为老年患者静脉给药替代方案——PhASAge研究
Nicolas Grégoire and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf381, https://doi.org/10.1093/jac/dkaf381
14
Real-life use of isavuconazole in Spanish children and adolescents
西班牙儿童和青少年中艾沙康唑的实际使用情况
Natalia Mendoza-Palomar and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf394, https://doi.org/10.1093/jac/dkaf394
15
No pharmacovigilance signal of intracranial hypertension associated with glycylcyclines: a FAERS-based disproportionality analysis
基于FAERS数据库的不成比例性分析：未发现甘氨酰环素类与颅内高压相关的药物警戒信号
Slobodan M Jankovic and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf395, https://doi.org/10.1093/jac/dkaf395
16
Posaconazole enteral tube administration in adults: pharmacokinetic target attainment of oral suspension compared with crushed delayed-release tablet
成人经肠内营养管给予泊沙康唑：口服混悬液与碾碎的缓释片的药代动力学目标达成情况比较
Nirjan Bhattarai and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf396, https://doi.org/10.1093/jac/dkaf396
17
Characterizing CYP3A4-mediated drug interactions: a fixed-sequence pharmacokinetic Chinese study of posaconazole and ruxolitinib in haematological malignancies
CYP3A4介导的药物相互作用特征：一项关于泊沙康唑和鲁索替尼在血液系统恶性肿瘤中的固定序列药代动力学中国研究
Beibei Liang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf398, https://doi.org/10.1093/jac/dkaf398
18
Differences in prescription for impetigo and cellulitis across years in three European countries
三个欧洲国家不同年份脓疱病和蜂窝织炎的处方差异
Thomas Bettuzzi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf400, https://doi.org/10.1093/jac/dkaf400
19
β-Lactam concentrations monitored in the early phase of community-acquired sepsis in the intensive care unit
重症监护室社区获得性脓毒症早期阶段监测的β-内酰胺浓度
Karolina Liljedahl Prytz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf401, https://doi.org/10.1093/jac/dkaf401
20
Enhanced antimycobacterial efficacy of simulated inhaled clofazimine versus oral clofazimine in combination with azithromycin and ethambutol in a hollow-fiber system
在空心纤维系统中，模拟吸入氯法齐明与口服氯法齐明联合阿奇霉素和乙胺丁醇的抗结核分枝杆菌疗效增强比较
Jelmer Raaijmakers and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf402, https://doi.org/10.1093/jac/dkaf402
21
Identification of antimicrobial resistance genes in Escherichia coli through network diffusion
通过网络扩散法鉴定大肠杆菌中的抗生素耐药基因
Anis Mansouri and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf404, https://doi.org/10.1093/jac/dkaf404
22
Preclinical evaluation of epetraborole in the hollow fibre system model of Mycobacterium abscessus lung disease
依培硼罗在脓肿分枝杆菌肺病空心纤维系统模型中的临床前评估
Sanjay Singh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf405, https://doi.org/10.1093/jac/dkaf405
23
The β-lactamase inhibitor concentration-dependent minimum inhibitory concentration (MICcBLI) as methodology to assess the pharmacokinetic/pharmacodynamic relationship of piperacillin/tazobactam for dosing optimization
β-内酰胺酶抑制剂浓度依赖性最低抑菌浓度（MICcBLI）作为评估哌拉西林/他唑巴坦药代动力学/药效动力学关系以优化给药的方法
Malin Andersson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf406, https://doi.org/10.1093/jac/dkaf406
24
Unravelling the triad of penicillin-binding proteins, β-lactamase activity, and mRNA dynamics in Pseudomonas aeruginosa AmpC induction
解析铜绿假单胞菌AmpC诱导过程中青霉素结合蛋白、β-内酰胺酶活性和mRNA动态的三元关系
Maria Montaner and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf408, https://doi.org/10.1093/jac/dkaf408
25
Unnoticed spread of linear VanA-plasmids in vancomycin-variable Enterococcus faecium strains across different regions: a diagnostics challenge
不同地区万古霉素可变型粪肠球菌菌株中线性VanA质粒的未被察觉的传播：一项诊断挑战
Ana C Almeida-Santos and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf409, https://doi.org/10.1093/jac/dkaf409
26
Switching from etravirine to doravirine in virologically suppressed people with HIV: results from the French multicentre SWEED observational study
在病毒学抑制的HIV感染者中从依曲韦林切换至多拉韦林：法国多中心SWEED观察性研究的结果
Romain Palich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf410, https://doi.org/10.1093/jac/dkaf410
27
HIV-1 drug resistance among pregnant and breastfeeding mothers and its association with paediatric HIV infections in the Dolutegravir era in Uganda
乌干达多替拉韦时代孕产妇及哺乳期母亲中HIV-1耐药情况及其与儿童HIV感染的关联
Anne Kapaata and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf411, https://doi.org/10.1093/jac/dkaf411
28
Outpatient antibiotic prescribing for medically attended respiratory syncytial virus, influenza, or human metapneumovirus illness among high-risk adults in rural Wisconsin, United States
美国威斯康星州农村地区高风险成人因呼吸道合胞病毒、流感或人偏肺病毒感染就诊时的门诊抗生素处方情况
Sarah C J Jorgensen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf412, https://doi.org/10.1093/jac/dkaf412
29
Omadacycline as a drug candidate for Mycobacterium avium infections: in vitro insights on single and combination therapies
奥马环素作为鸟分枝杆菌感染候选药物：单药及联合治疗的体外研究
Saskia E Mudde and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf413, https://doi.org/10.1093/jac/dkaf413
30
Post-pandemic trends in Streptococcus pneumoniae serotype epidemiology and antibiotic susceptibility in adults with invasive and non-invasive pneumococcal disease in the USA (2022–2023)
后疫情时代美国成人侵袭性与非侵袭性肺炎链球菌病血清型流行病学及抗生素敏感性趋势（2022-2023）
Mekki F Bensaci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf414, https://doi.org/10.1093/jac/dkaf414
31
Benznidazole pharmacokinetics in patients with chronic Chagas disease: association with demographic factors and adverse drug reactions
慢性恰加斯病患者苯芴醇药代动力学：与人口统计学因素及药物不良反应的关联
Gabriel P E Silveira and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf416, https://doi.org/10.1093/jac/dkaf416
32
Acquired antimicrobial resistance genes in Bordetella Species: a global genomic analysis
博德特氏菌属中获得的抗菌药物耐药基因：全球基因组分析
Biao Tang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf418, https://doi.org/10.1093/jac/dkaf418
33
Machine learning for personalized antimicrobial susceptibility breakpoints: (Adaptive clinical breakpoint interpretation)
基于机器学习的个性化抗菌药物敏感性折点制定（自适应临床折点解释）
Yinzheng Zhong and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf419, https://doi.org/10.1093/jac/dkaf419
34
Multicentre investigation of Wickerhamomyces anomalus fungemia in India: emerging resistance and mechanistic insights
印度异常威克汉姆酵母菌血症的多中心研究：新发耐药性及机制洞察
Shristi Verma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf420, https://doi.org/10.1093/jac/dkaf420
35
Reducing aztreonam/avibactam waste: insights from Monte Carlo simulations
减少氨曲南/阿维巴坦浪费：蒙特卡洛模拟的启示
Yeleen Fromage and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf421, https://doi.org/10.1093/jac/dkaf421
36
Nanoparticle-based co-delivery of ciprofloxacin and meropenem enhances synergistic activity against multidrug-resistant hypervirulent Klebsiella pneumoniae clinical isolates
基于纳米颗粒的环丙沙星与美罗培南共递送可增强对多重耐药高毒力肺炎克雷伯菌临床分离株的协同活性
Reham Mostafa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf422, https://doi.org/10.1093/jac/dkaf422
37
Development of population pharmacokinetic models of total and free piperacillin in critically ill children and young adults for Monte Carlo simulations and model-informed precision dosing
危重症儿童及青年总游离哌拉西林群体药代动力学模型开发：用于蒙特卡洛模拟及模型引导的精准给药
Sonya Tang Girdwood and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf423, https://doi.org/10.1093/jac/dkaf423
38
Reaching the target: time and dose required to achieve target vancomycin plasma concentrations in admitted patients
达标分析：住院患者达到目标万古霉素血浆浓度所需的时间与剂量
W Töpfer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf424, https://doi.org/10.1093/jac/dkaf424
39
Notable transmitted HIV drug resistance among people who inject drugs in Pakistan
巴基斯坦注射毒品人群中显著传播的HIV耐药性
Stephanie Melnychuk and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf425, https://doi.org/10.1093/jac/dkaf425
40
Synergistic but clinically unattainable: amoxicillin/ceftriaxone combination against ampicillin-susceptible Enterococcus faecium
协同但临床难以实现：阿莫西林/头孢曲松联合对氨苄西林敏感粪肠球菌的体外活性
Ahmed Ashrin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf426, https://doi.org/10.1093/jac/dkaf426
41
Pharmacodynamic studies of taniborbactam (VNRX-5133) combined with cefepime against β-lactamase–producing Gram-negative bacteria in a neutropenic murine thigh infection model
中性粒细胞减少小鼠大腿感染模型中他尼硼巴坦（VNRX-5133）联合头孢吡肟对产β-内酰胺酶革兰氏阴性菌的药效动力学研究
Panagiota-Christina Georgiou and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf431, https://doi.org/10.1093/jac/dkaf431
42
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.
非塞拉蒂亚属肠杆菌目细菌所致心内膜炎的流行病学及治疗
Clayton F Hausberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf432, https://doi.org/10.1093/jac/dkaf432
43
Enhanced activity of apramycin and apramycin-based combinations against Mycobacteroides abscessus
阿普拉霉素及其组合对脓肿分枝杆菌的增强活性
Yanqin Huang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf433, https://doi.org/10.1093/jac/dkaf433
44
Efflux-mediated multidrug resistance mechanism in Trichophyton indotineae and Trichophyton rubrum; role of ABC transporters and MFS gene
印度毛癣菌与红色毛癣菌中由ABC转运蛋白和MFS基因介导的流出泵型多重耐药机制
Dipika Shaw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf434, https://doi.org/10.1093/jac/dkaf434
45
Sphingobacterium spp. as intrinsic producers of SPI Ambler class B metallo-β-lactamases
鞘氨醇杆菌属作为SPI Ambler B类金属β-内酰胺酶的固有产生者
Delphine Girlich and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf436, https://doi.org/10.1093/jac/dkaf436
46
Global phylogeography and genomic characterization of blaNDM-1-positive carbapenem-resistant Acinetobacter soli
blaNDM-1阳性碳青霉烯耐药溶胶阿卡净菌的全球系统发育地理学及基因组特征
Pengpeng Min and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf437, https://doi.org/10.1093/jac/dkaf437
47
Pharmacokinetics and tolerability of one-month daily rifapentine for latent tuberculosis treatment in haemodialysis patients
血液透析患者潜伏性结核治疗中每月一次每日利福喷丁的药代动力学及耐受性
Thornthun Ueaphongsukkit and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf439, https://doi.org/10.1093/jac/dkaf439
48
In vitro susceptibility of cefepime-enmetazobactam, cefepime-taniborbactam and cefepime-zidebactam towards carbapenemase-producing Enterobacterales
头孢吡肟-恩美他唑巴坦、头孢吡肟-他尼硼巴坦及头孢吡肟-齐德巴坦对产碳青霉烯酶肠杆菌目的体外敏感性
Marion Dutkiewicz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf440, https://doi.org/10.1093/jac/dkaf440
49
In vitro efficacy of sulbactam/durlobactam combined with β-lactam antibiotics in Australian Mycobacterium abscessus isolates
舒巴坦/杜洛巴坦联合β-内酰胺类抗生素对澳大利亚脓肿分枝杆菌分离株的体外疗效
Kirby Patterson-Fahy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf441, https://doi.org/10.1093/jac/dkaf441
50
Harnessing CRISPR–Cas9 and CRISPRi systems to reverse antibiotic resistance in a clinical multidrug-resistant Escherichia coli isolate
利用CRISPR-Cas9及CRISPRi系统逆转临床多重耐药大肠杆菌分离株的抗生素耐药性
Ruonan Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf442, https://doi.org/10.1093/jac/dkaf442
51
Cotrimoxazole in the intensive care unit: an impossible task for the fixed association in real life?
重症监护室中复方磺胺甲噁唑的应用：固定组合在现实中的不可行性？
Manon Launay and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf443, https://doi.org/10.1093/jac/dkaf443
52
National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
哥伦比亚全国代表性调查：基于下一代测序的抗逆转录病毒耐药相关突变分析
Ernesto Martínez-Buitrago and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf444, https://doi.org/10.1093/jac/dkaf444
53
A model-based comparison of dose reduction strategies for fixed-dose dolutegravir-containing regimens
基于模型的含固定剂量多替拉韦方案减量策略比较
Laura Dickinson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf445, https://doi.org/10.1093/jac/dkaf445
54
Therapeutic drug monitoring and target attainment of unbound flucloxacillin in hospitalized patients with measured MICs (FLUTE)
住院患者中游离氟氯西林的治疗药物监测及目标达成情况（基于实测最低抑菌浓度的FLUTE研究）
Pjotr P Temme and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf447, https://doi.org/10.1093/jac/dkaf447
55
Nirmatrelvir-ritonavir addition to acute care formulary: a retrospective, multi-centre evaluation of quantitative economic and qualitative clinical outcomes
奈玛特韦/利托那韦纳入急症治疗目录：一项多中心回顾性评估定量经济与定性临床结果的研究
Jose Valdes Ledesma and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf448, https://doi.org/10.1093/jac/dkaf448
56
Local antibiotic resistance surveillance in nursing homes using lot quality assurance sampling: a feasibility study
采用批量质量保证抽样法对养老院进行本地抗生素耐药性监测的可行性研究
Sacha Kuil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf451, https://doi.org/10.1093/jac/dkaf451
57
High in vitro activity of the novel antimicrobial gepotidacin against Neisseria gonorrhoeae isolates in eight WHO Enhanced Gonococcal Antimicrobial Surveillance Programme countries in three WHO regions, 2021–24
2021-2024年，在世卫组织三个区域的八个世卫组织增强淋球菌抗菌药物监测计划国家中，新型抗菌药物吉皮达星对淋病奈瑟菌分离株的体外活性较高
Josefine Ahlstrand and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf452, https://doi.org/10.1093/jac/dkaf452
58
Despite increasing use of integrase inhibitors to treat HIV infection, resistance to this class remains stable
尽管整合酶抑制剂用于治疗HIV感染的使用量不断增加，但此类药物的耐药性仍保持稳定
Cathia Soulie and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf454, https://doi.org/10.1093/jac/dkaf454
59
Fine-needle aspiration in infected necrotizing pancreatitis in the delayed intervention era: a post hoc analysis of safety, microbiological yield and therapeutic implications
延迟干预时代感染性坏死性胰腺炎的细针穿刺抽吸术：安全性、微生物学检出率及治疗意义的事后分析
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf455, https://doi.org/10.1093/jac/dkaf455
60
β-Lactam dosing in critically ill children: predictors for target non-attainment
危重症儿童β-内酰胺类药物给药：未达目标浓度的预测因素
Stef Schouwenburg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf457, https://doi.org/10.1093/jac/dkaf457
61
Co-administration of triazoles with calcineurin or mammalian target of rapamycin inhibitors in solid organ transplant patients hospitalized with invasive aspergillosis
实体器官移植患者合并侵袭性曲霉病住院时三唑类药物与钙调磷酸酶抑制剂或哺乳动物雷帕霉素靶蛋白抑制剂的联合用药情况
Barbara Alexander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf461, https://doi.org/10.1093/jac/dkaf461
62
In vitro selection of cefiderocol-resistant mutants in Acinetobacter baumannii harbouring the most common carbapenemase genes
携带最常见碳青霉烯酶基因的鲍曼不动杆菌中头孢地尔耐药突变体的体外筛选
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf462, https://doi.org/10.1093/jac/dkaf462
63
Preventing resistance development in infections by OXA β-lactamase-producing Pseudomonas aeruginosa: correlating clinical outcomes with hollow-fibre model input
预防产OXA β-内酰胺酶铜绿假单胞菌感染耐药性的产生：将临床结局与中空纤维模型输入相关联
María M Montero and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf464, https://doi.org/10.1093/jac/dkaf464
64
A national pilot community pharmacy–led urinary tract infection service: clinical and patient-reported outcomes from 9077 consultations
全国社区药房主导的尿路感染服务试点项目：9077次咨询的临床结局和患者报告结局
Efi Mantzourani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf466, https://doi.org/10.1093/jac/dkaf466
65
Towards enhanced translational value: preclinical drug activity testing against actively multiplying, nutrient-starved and pellicle biofilm-embedded Mycobacterium abscessus
提高转化价值：针对活跃增殖、营养匮乏和生物膜包裹的脓肿分枝杆菌进行临床前药物活性测试
Henriëtte M Meliefste and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf468, https://doi.org/10.1093/jac/dkaf468
Research Letters（研究快报）
66
Novel multiresistance transposon Tn7731 in bovine Pasteurella multocida from Germany
德国牛源多杀性巴氏杆菌中新型多重耐药转座子Tn7731
Henrike Krüger-Haker and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf336, https://doi.org/10.1093/jac/dkaf336
67
Efficacy of eravacycline in difficult-to-treat (DTR) Acinetobacter baumannii bacteraemia in ICU: a case report
厄他培南治疗重症监护病房难治性鲍曼不动杆菌菌血症的疗效：一例病例报告
Monica Melchio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf347, https://doi.org/10.1093/jac/dkaf347
68
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
来特莫韦暴露的造血细胞移植受者中EB病毒感染和移植后淋巴增殖性疾病风险可能增加
Jose F Camargo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf348, https://doi.org/10.1093/jac/dkaf348
69
Dalbavancin dosing in a severely underweight woman with prosthetic valve endocarditis: the critical role of proactive therapeutic drug monitoring
达巴万星在严重体重不足人工瓣膜心内膜炎女性患者中的给药：主动治疗药物监测的关键作用
Ambra Barco and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf365, https://doi.org/10.1093/jac/dkaf365
70
Cefazolin-induced seizures in a haemodialysis patient with elevated serum and cerebrospinal fluid concentrations: a case report
血液透析患者头孢唑林血清和脑脊液浓度升高诱发癫痫：一例病例报告
Kohei Hasegawa and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf373, https://doi.org/10.1093/jac/dkaf373
71
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
使用聚丙烯腈膜进行连续性肾脏替代治疗的患者中卡泊芬净药代动力学治疗监测的回顾性分析
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf390, https://doi.org/10.1093/jac/dkaf390
72
Diffusion of OXA-48- and NDM-5-producing Klebsiella pneumoniae ST383 clone in Central Italy
产OXA-48和NDM-5的肺炎克雷伯菌ST383克隆在意大利中部的传播
Gloria D’Achille and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf397, https://doi.org/10.1093/jac/dkaf397
73
Durability of lenacapavir in viremic heavily treatment-experienced people with HIV: real-world data from the PRESTIGIO Registry
来那卡帕韦在病毒载量阳性且接受过大量抗逆转录病毒治疗的HIV感染者中的持久性：来自PRESTIGIO登记处的现实数据
Tommaso Clemente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf415, https://doi.org/10.1093/jac/dkaf415
74
Co-carriage of the oxazolidinone resistance genes cfr and optrA in a linezolid-resistant Staphylococcus rostri isolate from a pig-farm worker
猪场工人利奈唑胺耐药猪鼻支原体分离株中噁唑烷酮类耐药基因cfr和optrA的共携带情况
Gi Yong Lee and Soo-Jin Yang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf428, https://doi.org/10.1093/jac/dkaf428
75
Importance of reviewing the package insert from gradient strip manufacturers
梯度扩散法药敏纸片生产商说明书审阅的重要性
Mandy Wootton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf429, https://doi.org/10.1093/jac/dkaf429
76
One resistance gene, many transposons: repeated formation of compound and pseudo-compound transposons carrying the aphA1 kanamycin and neomycin resistance gene
一个耐药基因，多个转座子：携带aphA1卡那霉素和新霉素耐药基因的复合及假复合转座子的重复形成
Christopher J Harmer and Ruth M Hall
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf450, https://doi.org/10.1093/jac/dkaf450
77
Absence of lymphogranuloma venereum among men who have sex with men on PrEP receiving doxycycline postexposure prophylaxis
接受暴露后多西环素预防性治疗的暴露前预防用药男男性行为者中未发现性病淋巴肉芽肿
Cristina Gómez-Ayerbe and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf456, https://doi.org/10.1093/jac/dkaf456
78
In vitro activity of gepotidacin against Chlamydia trachomatis
吉皮达星对沙眼衣原体的体外活性
Arabella Touati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 1, January 2026, dkaf460, https://doi.org/10.1093/jac/dkaf460
Journal of Antimicrobial Chemotherapy Volume 81, Issue 2抗菌化疗杂志 81卷 2期
https://academic.oup.com/jac/issue
Viewpoints（观点）
1
Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
长效糖肽类：最需要它们的患者获取药物的障碍有哪些，如何克服？
Aleece MacPhail and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf471, https://doi.org/10.1093/jac/dkaf471
2
Redefining antifungal prophylaxis in acute leukaemia in the era of targeted therapies
靶向治疗时代急性白血病抗真菌预防的重新定义
Marcio Nucci and Johan Maertens
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag010, https://doi.org/10.1093/jac/dkag010
Reviews（综述）
3
Research progress on resistance mechanisms and clinical efficacy of tigecycline against Klebsiella pneumoniae
替加环素对肺炎克雷伯菌的耐药机制及临床疗效研究进展
Meilin Wu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf504, https://doi.org/10.1093/jac/dkaf504
4
Liposomal amphotericin B and renal safety: review of the evidence and clinical considerations
两性霉素B脂质体与肾脏安全性：证据回顾及临床考量
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf473, https://doi.org/10.1093/jac/dkaf473
5
Strategies for mitigating severe COVID-19 in patients with haematological malignancy during the omicron era
奥密克戎时代减轻血液系统恶性肿瘤患者严重新冠肺炎的策略
Keiji Okinaka and Joshua T Schiffer
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf489, https://doi.org/10.1093/jac/dkaf489
Systematic Reviews（系统综述）
6
Safety and efficacy of gepotidacin in urinary tract infection: a GRADE-assessed systematic review and meta-analysis
吉泊替达辛治疗尿路感染的安全性和有效性：一项基于GRADE评估的系统综述和荟萃分析
Taha Ibrahim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf469, https://doi.org/10.1093/jac/dkaf469
7
The emerging clinical relevance and antimicrobial resistance of Pluralibacter gergoviae: a systematic review
产吲哚金黄杆菌日益凸显的临床相关性和抗菌药物耐药性：一项系统综述
Bruna Abdul Ahad Saad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf476, https://doi.org/10.1093/jac/dkaf476
8
A comprehensive analysis of the mutational landscape determining polymyxin resistance in Klebsiella pneumoniae
决定肺炎克雷伯菌多粘菌素耐药性的突变谱综合分析
Sambit Kumar Dwibedy and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf503, https://doi.org/10.1093/jac/dkaf503
9
Factors promoting or hindering self-administered outpatient parenteral antimicrobial therapy: a systematic literature review
促进或阻碍自我给药门诊静脉注射抗菌药物治疗的因素：一项系统文献综述
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf490, https://doi.org/10.1093/jac/dkaf490
Original Research（论著）
10
Cefepime/enmetazobactam for Gram-negative periprosthetic joint infections? A randomized porcine study on target tissue pharmacokinetics
头孢吡肟/恩美唑巴坦治疗革兰氏阴性假体周围关节感染？一项关于猪的靶组织药代动力学的随机研究
M B D Nielsen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf487, https://doi.org/10.1093/jac/dkaf487
11
Impact of extracorporeal membrane oxygenation modes on voriconazole exposure in critically ill patients
体外膜肺氧合模式对危重患者伏立康唑暴露的影响
Xinrui Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf501, https://doi.org/10.1093/jac/dkaf501
12
Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic -pharmacodynamic modelling in adults and infants
基于模型通过成人和婴儿群体药代动力学-药效学模型评估VRC07-523LS在婴儿中的给药方案
Dustin Huynh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf449, https://doi.org/10.1093/jac/dkaf449
13
Antibiotic resistance of Pseudomonas aeruginosa strains—intracellular metabolomics analysis
铜绿假单胞菌菌株的抗生素耐药性——细胞内代谢组学分析
Karolina Anna Mielko-Niziałek and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf453, https://doi.org/10.1093/jac/dkaf453
14
In vitro activity of cefepime/zidebactam against sulbactam/durlobactam-susceptible and -resistant Acinetobacter baumannii clinical isolates
头孢吡肟/齐多巴坦对舒巴坦/杜洛巴坦敏感和耐药鲍曼不动杆菌临床分离株的体外活性
Carlo Tascini and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf467, https://doi.org/10.1093/jac/dkaf467
15
Prevalence of macrolide resistance in Mycoplasma pneumoniae in The Netherlands
荷兰肺炎支原体大环内酯类抗生素耐药性的流行情况
Patrick D J Sturm and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf475, https://doi.org/10.1093/jac/dkaf475
16
Simulated lung exposure in pneumonia patients to evaluate the antibacterial capacity and resistance suppression of clinical tigecycline regimens against carbapenem-resistant
Acinetobacter baumannii
模拟肺炎患者肺部暴露情况以评估临床替加环素方案对碳青霉烯类耐药鲍曼不动杆菌的抗菌能力和耐药抑制作用
Xiaonan Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf477, https://doi.org/10.1093/jac/dkaf477
17
Enterococcus faecium harbouring vanA, optrA and cfr(D) on a linear plasmid in Canada: a CANWARD surveillance case
加拿大发现携带vanA、optrA和cfr(D)的粪肠球菌线性质粒：一项CANWARD监测病例
Melissa McCracken and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf478, https://doi.org/10.1093/jac/dkaf478
18
The effect of intrauterine exposure to aminoglycosides on neonatal hearing
宫内暴露于氨基糖苷类抗生素对新生儿听力的影响
Daniel Leshin-Carmel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf483, https://doi.org/10.1093/jac/dkaf483
19
Ceftazidime/avibactam: a potent arsenal against multidrug-resistant Pseudomonas aeruginosa-unveiling in vitro and in vivo strategies
头孢他啶/阿维巴坦：对抗多重耐药铜绿假单胞菌的有力武器——揭示体内外策略
Jiaju Zhuo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf495, https://doi.org/10.1093/jac/dkaf495
20
Comparison of disk diffusion, MIC test strip and broth microdilution for eravacycline susceptibility testing of 422 Staphylococcus aureus isolates using ChinaCAST breakpoints
采用中国CAST折点，比较422株金黄色葡萄球菌对依拉环素的纸片扩散法、最低抑菌浓度测试条法和肉汤微量稀释法的敏感性测试结果
Xinying Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf502, https://doi.org/10.1093/jac/dkaf502
21
Penetration of daptomycin in cerebrospinal fluid during pneumococcal meningitis
肺炎链球菌性脑膜炎期间达托霉素在脑脊液中的渗透情况
Pascal Chavanet and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf474, https://doi.org/10.1093/jac/dkaf474
22
Rapid molecular diagnostics for detection of extensively drug-resistant Salmonella Typhi
用于检测广泛耐药伤寒沙门菌的快速分子诊断技术
Emma L Sweeney and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf481, https://doi.org/10.1093/jac/dkaf481
23
Gender inequality and antibiotic consumption: analysis of pharmaceutical sales data from 70 countries, 2000–22
性别不平等与抗生素消费：基于2000 - 2022年70个国家药品销售数据的分析
Deepshikha Batheja and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag002, https://doi.org/10.1093/jac/dkag002
24
Real-world evaluation of isavuconazole in children with cancer
伊沙康唑在儿童癌症患者中的现实应用评估
Janine Nijhuis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf485, https://doi.org/10.1093/jac/dkaf485
25
Assessing antimicrobial susceptibility testing guideline adherence by laboratories providing bacteriology services in Ghana: a pilot study
加纳提供细菌学服务的实验室对抗菌药物敏感性试验指南依从性的评估：一项试点研究
Joseph Elikem Efui Acolatse and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag003, https://doi.org/10.1093/jac/dkag003
26
Resistance to second-generation integrase inhibitors in people with HIV following treatment failure on dolutegravir- or bictegravir-based ART in Taiwan
台湾地区基于多替拉韦或比克替拉韦的抗逆转录病毒治疗失败后，HIV感染者对第二代整合酶抑制剂的耐药性
Guan-Jhou Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf488, https://doi.org/10.1093/jac/dkaf488
27
In vitro activity of gepotidacin against a challenging panel of multidrug-resistant Neisseria gonorrhoeae isolates
吉泊西汀对一组具有挑战性的多重耐药淋病奈瑟菌分离株的体外活性
Michelle Jayne Cole and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag001, https://doi.org/10.1093/jac/dkag001
28
A disproportionality analysis of adverse events associated with omadacycline based on the FDA adverse event reporting system database
基于美国食品药品监督管理局（FDA）不良事件报告系统数据库的奥马环素相关不良事件比例失衡分析
Ye-Lei Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag006, https://doi.org/10.1093/jac/dkag006
29
Weight-band-based simplification of oral allometric miltefosine dosing in paediatric patients with visceral leishmaniasis
基于体重范围的口服异速缩放米替福新给药方案在儿童内脏利什曼病患者中的简化应用
Andres Mazariegos Herrera and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag014, https://doi.org/10.1093/jac/dkag014
30
evelopment of a capability framework for antimicrobial stewardship specialist health professionals working in the NHS in England: utilizing Delphi methodology
运用德尔菲法为在英国国家医疗服务体系（NHS）中工作的抗菌药物管理专业人员制定能力框架
Ryan A Hamilton and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf438, https://doi.org/10.1093/jac/dkaf438
31
First characterization of insertions in the HIV-1 integrase-coding region from people with HIV
首次对来自艾滋病病毒感染者的HIV-1整合酶编码区插入情况进行特征分析
Nhat Quang Tu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf491, https://doi.org/10.1093/jac/dkaf491
32
Development of an impedance-based fast antimicrobial susceptibility test for Neisseria gonorrhoeae
开发一种基于阻抗的淋病奈瑟菌快速抗菌药物敏感性检测方法
Caitlin N Daniels and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf493, https://doi.org/10.1093/jac/dkaf493
33
Juvenile toxicity and developmental safety of Zintrodiazine, a novel antimalarial candidate, in Wistar rats
新型抗疟候选药物Zintrodiazine在Wistar大鼠中的幼年毒性和发育安全性研究
Hitesh A Kadu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag008, https://doi.org/10.1093/jac/dkag008
34
Do the redefined EUCAST susceptibility categories warrant adjustment of paediatric antibiotic dosages? Pragmatic physiologically based pharmacokinetic modelling of four commonly used agents
欧洲抗微生物药物敏感性试验委员会（EUCAST）重新定义的敏感性分类是否需要调整儿童抗生素剂量？——对四种常用药物的实用生理药代动力学建模研究
Marika A de Hoop-Sommen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf463, https://doi.org/10.1093/jac/dkaf463
35
Exploring the opportunity for therapeutic drug monitoring (TDM) and precision dose antimicrobials in an outpatient antimicrobial therapy (OPAT) service: a prospective observational study
门诊抗菌治疗（OPAT）服务中开展治疗药物监测（TDM）和精准剂量抗菌治疗的机遇：一项前瞻性观察研究
R C Wilson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf484, https://doi.org/10.1093/jac/dkaf484
36
Impact of sex, age and body composition on rilpivirine and cabotegravir trough concentrations in people with HIV receiving long-acting injectable antiretroviral therapy
性别、年龄和身体成分对接受长效注射用抗逆转录病毒治疗的HIV感染者利匹韦林和卡博特韦谷浓度的影响
Maria Vittoria Cossu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag024, https://doi.org/10.1093/jac/dkag024
37
Pharmacokinetics of cefiderocol during prolonged intermittent kidney replacement therapy in two patients with septic shock
头孢地尔在两例感染性休克患者长时间间歇性肾脏替代治疗期间的药代动力学
Julius J Schmidt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf496, https://doi.org/10.1093/jac/dkaf496
38
Understanding mechanisms of reduced cefiderocol susceptibility in pvdS and fecI mutants of Pseudomonas aeruginosa
了解铜绿假单胞菌pvdS和fecI突变体对头孢地尔敏感性降低的机制
Yoshinori Yamano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag004, https://doi.org/10.1093/jac/dkag004
39
Biomarker-informed PBPK modelling of meropenem in paediatric severe pneumonia: implications for target-site PK/PD
基于生物标志物的美罗培南在儿童重症肺炎中的生理药动学模型构建：对靶部位药代动力学/药效学的影响
Yao Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf500, https://doi.org/10.1093/jac/dkaf500
40
Evaluating hypoalbuminaemia thresholds associated with delayed blood sterilization among patients receiving cefazolin or antistaphylococcal penicillins for MSSA bacteraemia
评估接受头孢唑林或抗葡萄球菌青霉素治疗甲氧西林敏感金黄色葡萄球菌（MSSA）菌血症患者中，与血液延迟灭菌相关的低白蛋白血症阈值
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf498, https://doi.org/10.1093/jac/dkaf498
Research Letters（研究快讯）
41
False-negative result in fourth-generation HIV screening tests after weak detection of p24 antigen in the context of inappropriate post-exposure prophylaxis use: a case report
不当使用暴露后预防用药导致第四代HIV筛查试验p24抗原弱检出后出现假阴性结果：一例病例报告
J Kimmerlin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf459, https://doi.org/10.1093/jac/dkaf459
42
Proposal for the nomenclature of tmexCD-toprJ-like gene clusters
关于tmexCD-toprJ样基因簇命名的建议
Chengzhen Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf482, https://doi.org/10.1093/jac/dkaf482
43
IS26-mediated chromosomal integration of virulence plasmid fragments in ST2237 carbapenem-resistant Klebsiella pneumoniae
IS26介导的毒力质粒片段在ST2237型碳青霉烯耐药肺炎克雷伯菌染色体中的整合
Yan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag018, https://doi.org/10.1093/jac/dkag018
Letter to the Editor（致编辑的信）
44
Comment on: Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes
对“采用聚丙烯腈膜对接受连续性肾脏替代治疗的患者进行卡泊芬净药代动力学监测的回顾性分析”的评论
Gwénola Marais and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf465, https://doi.org/10.1093/jac/dkaf465
45
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy-right-to-reply
意大利米兰地区使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性传播感染的抗菌药物使用情况——回应说明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkag027, https://doi.org/10.1093/jac/dkag027
ACKNOWLEDGEMENT OF REFEREES（鸣谢审稿专家）
46
Acknowledgement of Referees
鸣谢审稿专家
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf417, https://doi.org/10.1093/jac/dkaf417
CORRECTION（更正）
47
Correction to: Comment on: Antiviral effect of Evusheld in COVID-19 hospitalized patients infected with pre-Omicron or Omicron variants: a modelling analysis of the randomized DisCoVeRy trial
更正：关于Evusheld在感染奥密克戎变异株前或奥密克戎变异株的新冠住院患者中的抗病毒效果：对随机DisCoVeRy试验的建模分析的评论
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 2, February 2026, dkaf492, https://doi.org/10.1093/jac/dkaf492
Journal of Antimicrobial Chemotherapy Volume 81, Issue 3抗菌化疗杂志 81卷 3期
https://academic.oup.com/jac/issue
REVIEW（综述）
1
Closing the PrEP access gap in Europe: a strategic framework for equity and innovation among difficult-to-reach populations
缩小欧洲暴露前预防获取差距：面向难以触及（PrEP）人群的公平与创新战略框架
Josep M Llibre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag052, https://doi.org/10.1093/jac/dkag052
2
Precision dosing of systemic antifungals in adults: therapeutic drug monitoring, empiric dose optimization and barriers to implementation
成人全身性抗真菌药物的精准给药：治疗药物监测、经验性剂量优化及实施障碍
Daniel B Chastain and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag055, https://doi.org/10.1093/jac/dkag055
3
Bacterial DNA topoisomerase IV and DNA gyrase inhibitors: history of the quinolones, their clinical usage and potential alternatives for the future
细菌DNA拓扑异构酶IV和DNA旋转酶抑制剂：喹诺酮类药物的历史、临床应用及未来潜在替代方案
Daisuke Fukuda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag054, https://doi.org/10.1093/jac/dkag054
4
Combating multidrug-resistant Klebsiella pneumoniae: current therapeutic regimens and future directions
应对多重耐药肺炎克雷伯菌：当前治疗方案与未来方向
Robiul Islam and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag064, https://doi.org/10.1093/jac/dkag064
SYSTEMATIC REVIEW（系统综述）
5
Global and regional prevalence of metallo-β-lactamases in carbapenem-resistant Acinetobacter baumannii: a systematic review and meta-analysis
耐碳青霉烯类鲍曼不动杆菌中金属β-内酰胺酶的全球和区域流行情况：一项系统综述和荟萃分析
Stamatis Karakonstantis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag037, https://doi.org/10.1093/jac/dkag037
Original Research（论著）
6
The effect of oral ciprofloxacin at conventional doses on the QT interval in a tertiary outpatient setting
三级门诊常规剂量口服环丙沙星对患者QT间期的影响
Weber Liu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag020, https://doi.org/10.1093/jac/dkag020
7
Bictegravir concentrations in breastmilk of healthy, lactating women without HIV
未感染人类免疫缺陷病毒（HIV）的健康哺乳期女性乳汁中的比克替拉韦浓度
L C van der Wekken-Pas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag022, https://doi.org/10.1093/jac/dkag022
8
Management and outcomes of Stenotrophomonas maltophilia recovered from deep-site clinical specimens: a bicentric retrospective cohort study
从深部部位临床标本中分离出的嗜麦芽窄食单胞菌的治疗及转归：一项双中心回顾性队列研究
Anastasia Saade and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag021, https://doi.org/10.1093/jac/dkag021
9
Development of a risk prediction model for vancomycin-associated acute kidney injury: a multicentre retrospective study
万古霉素相关急性肾损伤风险预测模型的建立：一项多中心回顾性研究
Tomoyuki Ishigo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag012, https://doi.org/10.1093/jac/dkag012
10
Cooperation between HIV-1 integrase natural polymorphism K156N and 3′PPT mutations in dolutegravir monotherapy failure
HIV-1 整合酶天然多态性 K156N 与 3′PPT 突变在多替拉韦单药治疗失败中的协同作用
Jolieke A T van Osch and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag033, https://doi.org/10.1093/jac/dkag033
11
Impact of body mass index and serum albumin levels on isavuconazole plasma concentrations in patients with haematological malignancies
体重指数和血清白蛋白水平对血液系统恶性肿瘤患者艾沙康唑血浆浓度的影响
Jie Gao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag032, https://doi.org/10.1093/jac/dkag032
12
Pharmacokinetics of cefotaxime and its metabolite desacetyl-cefotaxime to optimize dosing in critically ill children and children with sickle cell disease
用以优化危重症儿童和镰状细胞病儿童给药剂量的头孢噻肟及其代谢产物去乙酰头孢噻肟的药代动力学研究
Seef Abdalla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag019, https://doi.org/10.1093/jac/dkag019
13
Summary of ceftriaxone-resistant Neisseria gonorrhoeae in Canada, 2017–24
2017 - 2024年加拿大头孢曲松耐药淋病奈瑟菌情况汇总
Robyn Thorington and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag007, https://doi.org/10.1093/jac/dkag007
14
Improving perioperative prophylactic antibiotic prescribing using a novel decision-support tool
使用新型决策支持工具改进围手术期预防性抗生素处方
Mark Mcintyre and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag015, https://doi.org/10.1093/jac/dkag015
15
Comparative activity of established versus new-generation β-lactams against AmpC-hyperproducing clinical isolates of Enterobacter cloacae complex and Klebsiella aerogenes: a multicentre study
针对产超广谱AmpC酶的阴沟肠杆菌复合群和产气克雷伯菌临床分离株，比较已上市与新一代β-内酰胺类抗生素的抗菌活性：一项多中心研究
Ángel Rodríguez-Villodres and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag034, https://doi.org/10.1093/jac/dkag034
16
Impact of eravacycline on fibrinogen
依拉环素对纤维蛋白原的影响
Emily Stevenson and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag030, https://doi.org/10.1093/jac/dkag030
17
Biliary pharmacokinetic/pharmacodynamic analysis of continuous infusion ceftazidime–avibactam in a case series of orthotopic liver transplant recipients
原位肝移植受者连续输注头孢他啶-阿维巴坦的药代动力学/药效学胆系分析：一项病例系列研究
Milo Gatti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag009, https://doi.org/10.1093/jac/dkag009
18
Autoaggregation-associated carbapenem tolerance mediated by mrkH inactivation identified from a cohort of Klebsiella pneumoniae species complex clinical isolates
从肺炎克雷伯菌复合群临床分离株队列中鉴定出由mrkH失活介导的与自动聚集相关的碳青霉烯耐受性
Natsuki Yamanaka and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag017, https://doi.org/10.1093/jac/dkag017
19
In vitro activity of double and triple antimicrobial combinations against carbapenem-resistant Pseudomonas aeruginosa biofilm
双联和三联抗菌药物组合对碳青霉烯耐药铜绿假单胞菌生物膜的体外活性研究
Si-Ho Kim and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag031, https://doi.org/10.1093/jac/dkag031
20
LYSC98 as a novel vancomycin-derived agent effective against antibiotic-resistant pathogens in tolerant state
LYSC98作为一种新型万古霉素衍生物，对耐受状态下的耐药病原体有效
Xing Xia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag036, https://doi.org/10.1093/jac/dkag036
21
HBV status modulates transaminase decrease after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in people with HIV
HIV感染者从富马酸替诺福韦二吡呋酯切换为丙酚替诺福韦后，HBV状态对转氨酶下降的调节作用
Giuseppe Lapadula and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag045, https://doi.org/10.1093/jac/dkag045
22
Pharmacokinetics of colistin in adult critically ill patients in South Africa
南非成人危重症患者中多黏菌素的药代动力学研究
Veshni Pillay-Fuentes Lorente and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag011, https://doi.org/10.1093/jac/dkag011
23
Antifungal susceptibility surveillance of clinical moulds to olorofim, manogepix, amphotericin B, triazoles and echinocandins at 10 tertiary hospitals in China (2019–24)
2019 - 2024年中国10家三级医院临床霉菌对奥罗芬净、马诺盖匹克斯、两性霉素B、三唑类和棘白菌素类抗真菌药的敏感性监测
Su Chen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag016, https://doi.org/10.1093/jac/dkag016
24
Short-cycle three-day-per-week efavirenz/emtricitabine/tenofovir disoproxil fumarate therapy: a seven-year extension study
短周期每周三日依非韦伦/恩曲他滨/富马酸替诺福韦二吡呋酯疗法：一项为期七年的延长研究
Beatriz Borjabad and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag040, https://doi.org/10.1093/jac/dkag040
25
Risk of hypertension in people with HIV in the USA initiating modern antiretroviral regimens: pooled analysis of blood pressure data from five clinical trials
美国感染HIV者启动现代抗逆转录病毒治疗方案后患高血压的风险：五项临床试验血压数据汇总分析
Priscilla Y Hsue and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag005, https://doi.org/10.1093/jac/dkag005
26
Real-world drug monitoring of dalbavancin using a three-dose regimen of 1500mg at days 1, 15 and 43 in bone and joint or cardiovascular infection
采用第1、15和43天各1500毫克的三剂量方案对达巴万星（Dalbavancin）在骨关节或心血管感染治疗中的实际药物监测研究
Thomas Lin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag039, https://doi.org/10.1093/jac/dkag039
27
Nationwide patterns of HIV drug resistance and high viral load in Sub-Saharan African countries
撒哈拉以南非洲国家全国范围内的HIV耐药及高病毒载量模式
Abubaker Ibrahim Elbur and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf497, https://doi.org/10.1093/jac/dkaf497
28
Risk factors for suboptimal target attainment of commonly used ß-lactam antibiotics in older adults: a prospective cohort study
老年人常用β-内酰胺类抗生素未达最佳治疗目标的风险因素：一项前瞻性队列研究
Arnaud De Clercq and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag048, https://doi.org/10.1093/jac/dkag048
29
Physiologically based pharmacokinetic modelling to optimize dosing regimen of biapenem in renal impairment and elderly populations
基于生理的药代动力学模型优化肾功能不全及老年人群比阿培南给药方案
Wenyan Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf499, https://doi.org/10.1093/jac/dkaf499
30
Early targeted therapy guided by rapid phenotypic antimicrobial susceptibility testing in critically ill patients with Gram-negative bacterial bloodstream infections: a retrospective cohort study
快速表型抗菌药物敏感性试验指导下的早期目标性治疗对革兰氏阴性菌血流感染危重患者的效果：一项回顾性队列研究
Salvatore Rotundo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag056, https://doi.org/10.1093/jac/dkag056
31
Impact of COVID-19-related healthcare changes on antibiotic resistance in clinical Escherichia coli isolates: interrupted time series analyses in Scotland, UK
与新冠肺炎相关的医疗变化对英国苏格兰地区临床大肠杆菌分离株抗生素耐药性的影响：中断时间序列分析
Laura Ciaccio and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag049, https://doi.org/10.1093/jac/dkag049
32
Multicentre evaluation of teicoplanin prescribing and monitoring in the UK and Ireland: the TUcK–SHOP study
英国和爱尔兰替考拉宁处方与监测的多中心评估：TUcK–SHOP研究
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag038, https://doi.org/10.1093/jac/dkag038
33
Diabetes and risk of significant fibrosis in adults with HIV and metabolic dysfunction-associated steatotic liver disease: a prospective cohort study
糖尿病与HIV合并代谢功能障碍相关脂肪性肝病成人患者发生显著肝纤维化的风险：一项前瞻性队列研究
Win Min Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag053, https://doi.org/10.1093/jac/dkag053
34
A pharmacovigilance analysis of carbapenem-related utilizing the FDA adverse event reporting system (FAERS) database from 2013 to 2025
基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库2013 - 2025年数据的碳青霉烯类相关药物警戒分析
Connor Frey and Parham Elmi
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag060, https://doi.org/10.1093/jac/dkag060
35
Effects of extracorporeal membrane oxygenation on the pharmacokinetics and tissue penetration rates of vancomycin and linezolid: data from Landrace pigs
体外膜肺氧合对万古霉素和利奈唑胺药代动力学及组织穿透率的影响：来自长白猪的数据
Huifang Zhang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag063, https://doi.org/10.1093/jac/dkag063
36
Switching to bictegravir/emtricitabine/tenofovir alafenamide in people with HIV and prior resistance mutations. Data from the Italian ARCA cohort: the BIC-BARRIER study. B/F/TAF switch: mutations and outcomes
在既往存在耐药突变的人类免疫缺陷病毒（HIV）感染者中换用比克替拉韦/恩曲他滨/丙酚替诺福韦治疗。来自意大利ARCA队列的数据：BIC-BARRIER研究。比克替拉韦/恩曲他滨/丙酚替诺福韦（B/F/TAF）换药方案：耐药突变与治疗结果
Laura Pezzati and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag035, https://doi.org/10.1093/jac/dkag035
37
A two-stage diagnostic model for discriminating and assessing risk of meropenem heteroresistance in Pseudomonas aeruginosa
用于鉴别和评估铜绿假单胞菌对美罗培南异质性耐药风险的二阶段诊断模型
Yali Fan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag061, https://doi.org/10.1093/jac/dkag061
38
Microdialysis assessment of gentamicin for second-line antimicrobial prophylaxis in abdominal surgery
微透析评估庆大霉素在腹部手术中作为二线抗菌预防药物的效果
Quentin Saint-Genis and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag071, https://doi.org/10.1093/jac/dkag071
39
Genetic and clinical predictors of voriconazole pharmacokinetics and hepatotoxicity: focused on CYP2C19 normal and intermediate metabolizers
伏立康唑药代动力学及肝毒性的遗传和临床预测因素：聚焦于CYP2C19正常代谢型和中间代谢型
Hui Li and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag065, https://doi.org/10.1093/jac/dkag065
40
Stakeholder perspectives on the offer and acceptance of self-administration of outpatient parenteral antimicrobial therapy: a qualitative study
利益相关者对提供和接受门诊患者自行注射抗菌药物治疗的看法：一项定性研究
Hester H Stoorvogel and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag068, https://doi.org/10.1093/jac/dkag068
41
Is current guidance for cloxacillin prophylaxis dosages in hip and knee arthroplasty adequate? Evidence from a prospective Swedish cohort
当前髋关节和膝关节置换术中氯唑西林预防性用药剂量指南是否充分？来自一项前瞻性瑞典队列研究的证据
Katja Wallander and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag067, https://doi.org/10.1093/jac/dkag067
42
Effect of pretreatment HIV drug resistance on mortality, attrition and viral suppression in patients initiating antiretroviral therapy and genetic transmission network: an observational cohort study in Southwest China
治疗前HIV药物耐药性对开始接受抗逆转录病毒治疗患者的死亡率、失访率和病毒抑制率的影响以及遗传传播网络：中国西南地区一项观察性队列研究
Litai Qin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag073, https://doi.org/10.1093/jac/dkag073
RESEARCH LETTER（研究快讯）
43
Varicella and varicella zoster virus meningoencephalitis in a diffuse large B-cell lymphoma patient after chimeric antigen receptor-T-cell therapy
嵌合抗原受体T细胞疗法后，弥漫性大B细胞淋巴瘤患者发生水痘及水痘-带状疱疹病毒脑膜脑炎
Yan Feng and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag041, https://doi.org/10.1093/jac/dkag041
44
The ‘double hit’ on dalbavancin pharmacokinetics: hypertriglyceridaemia and augmented renal clearance in a child with glycogen storage disease type Ib
糖原累积病Ib型患儿中，高甘油三酯血症和肾清除率增加对达巴万星药代动力学的“双重打击”
Bianca Monti and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag028, https://doi.org/10.1093/jac/dkag028
45
Tn7860, a novel chromosomal pseudo-compound transposon carrying the OptrA gene in Enterococcus faecalis
Tn7860，粪肠球菌中携带OptrA基因的一种新型染色体假复合转座子
Francesca Romana Massacci and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag046, https://doi.org/10.1093/jac/dkag046
46
HBV reactivation after switching to cabotegravir plus rilpivirine therapy among people living with HIV: do not forget the reservoir
HIV感染者换用卡博特韦（cabotegravir）联合利匹韦林（rilpivirine）治疗后乙肝病毒再激活：切勿忽视病毒储存库
Rémi Rouget and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag050, https://doi.org/10.1093/jac/dkag050
47
An inoperable mediastinal infection involving vascular graft treated with weekly oritavancin as chronic suppressive therapy. A case report with pharmacokinetic data
一例涉及血管移植物的无法手术的纵隔感染，采用每周一次的奥利万星作为慢性抑制疗法。附药代动力学数据的病例报告
Pierangelo Chinello and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag013, https://doi.org/10.1093/jac/dkag013
48
Evaluation of the Carbapenemase Detection Kit (Colloidal Gold; Macro & Micro Test): a new immunochromatographic assay for rapid detection of carbapenemases in Enterobacterales
碳青霉烯酶检测试剂盒（胶体金法；宏基因与微基因检测法）评估：一种用于快速检测肠杆菌目细菌中碳青霉烯酶的新型免疫层析法
Hippolyte De Swardt and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag066, https://doi.org/10.1093/jac/dkag066
49
Cefalexin use in UK acute pyelonephritis practice: unaddressed challenges in dosing, breakpoints and clinical evidence
头孢氨苄在英国急性肾盂肾炎治疗中的应用：给药、断点和临床证据方面尚未解决的挑战
Stephen Hughes and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag051, https://doi.org/10.1093/jac/dkag051
LETTERS TO THE EDITOR（致编辑的信）
50
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy
评论：意大利米兰多西环素暴露后预防（DoxyPEP）使用者中用于治疗细菌性性传播感染的抗菌药物使用情况
Chris Kenyon
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag025, https://doi.org/10.1093/jac/dkag025
51
Possible increased risk of Epstein–Barr virus (EBV) infection and post-transplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients: right-to-reply
来特莫韦暴露的造血细胞移植受者发生EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加：答复权
Jose F Camargo and Anthony D Anderson
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag043, https://doi.org/10.1093/jac/dkag043
52
Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis (DoxyPEP) users in Milan, Italy—right-to-reply
意大利米兰市使用多西环素暴露后预防（DoxyPEP）人群中，用于治疗细菌性性传播感染的抗菌药物使用情况——答复权声明
Angelo Roberto Raccagni and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag026, https://doi.org/10.1093/jac/dkag026
53
Comment on: Artificial intelligence for improving decision-making in bacterial infection management
述评：人工智能在细菌感染管理决策中的优化作用
Daniele Roberto Giacobbe
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag078, https://doi.org/10.1093/jac/dkag078
CORRECTION（更正）
54
Correction to: Bayesian estimation of the prevalence of antimicrobial resistance: a mathematical modelling study
更正：抗菌药物耐药性流行率的贝叶斯估计：一项数学建模研究
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkaf494, https://doi.org/10.1093/jac/dkaf494
55
Correction to: National representative survey of pretreatment HIV drug resistance in Colombia: analysis of antiretroviral resistance-associated mutations using next-generation sequencing
更正：哥伦比亚具有全国代表性的治疗前HIV耐药性调查：使用下一代测序技术分析抗逆转录病毒耐药相关突变
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 3, March 2026, dkag057, https://doi.org/10.1093/jac/dkag057
Journal of Antimicrobial Chemotherapy Volume 81, Issue 4抗菌化疗杂志81卷 4期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
GARROD LECTURE（加罗德讲座）
1
Garrod lecture: achieving the UNGA AMR mortality reduction goals
加罗德讲座：实现联合国大会抗菌药物耐药性死亡率降低目标
Ramanan Laxminarayan
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag082, https://doi.org/10.1093/jac/dkag082
REVIEW（综述）
2
25 years of improvement in mortality in invasive aspergillosis in haematology patients: will it be sustained or is it under threat?
侵袭性曲霉病血液病患者25年死亡率改善情况：这种改善能否持续，还是正受到威胁？
Johan A Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag077, https://doi.org/10.1093/jac/dkag077
3
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 2: from molecule to confirmed hit
针对锥虫病的从高质量潜在客户和药物开发候选者出发的战略发现路线图。第二部分：从分子到确证活性分子
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag110, https://doi.org/10.1093/jac/dkag110
VIRTUAL ROUNDTABLE（虚拟圆桌会议）
4
Diagnosis and risk factors for invasive mould disease—a round table discussion on directing antifungal therapy according to the available evidence
侵袭性霉菌病的诊断与危险因素——根据现有证据指导抗真菌治疗的圆桌讨论
Ana Alastruey-Izqueirdo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag062, https://doi.org/10.1093/jac/dkag062
EDITORIALS, MESSAGES FROM THE OUTGOING AND INCOMING EDITORS-IN-CHIEF（社论、离任与就任主编寄语）
5
Message from the incoming Editor-in-Chief of JAC
《抗菌化疗杂志》就任主编寄语
Monica A Slavin
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf479, https://doi.org/10.1093/jac/dkaf479
6
Message from the outgoing Editor-in-Chief
离任主编寄语
J Peter Donnelly
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf480, https://doi.org/10.1093/jac/dkaf480
REVIEW（综述）
7
Experimental biofilm models for pharmacokinetic and pharmacodynamic investigations: bridging in vitro, ex vivo and in vivo systems
用于药代动力学和药效学研究的实验性生物膜模型：连接体外、离体和体内系统
Stephanie Supparitsch and Markus Zeitlinger
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag091, https://doi.org/10.1093/jac/dkag091
8
Antimicrobial therapy for infected necrotizing pancreatitis: microbiology, antimicrobial resistance and pharmacokinetics
感染性坏死性胰腺炎的抗菌治疗：微生物学、抗菌药物耐药性及药代动力学
Hannah S Pauw and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag092, https://doi.org/10.1093/jac/dkag092
9
Continuous linezolid infusion: the new way to dose, the old risks to fear
持续输注利奈唑胺：新的给药方式，仍需警惕旧有风险
Daniel Muñoz-Pichuante and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag100, https://doi.org/10.1093/jac/dkag100
10
Alignment of national standard treatment guidelines with WHO AWaRe recommendations for adult primary care infectious diseases: implications for antimicrobial stewardship
将国家标准治疗指南与世卫组织（WHO）针对成人初级保健传染病的“慎用、监测、备用”（AWaRe）推荐意见相统一：对抗菌药物管理的影响
Huda Arooj and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag099, https://doi.org/10.1093/jac/dkag099
SYSTEMATIC REVIEW（系统综述）
11
Healthcare providers’ experiences in caring for MDRO carriers with a focus on the moral dimensions of care: a systematic review
医疗服务提供者护理多重耐药菌（MDRO）携带者的经历——聚焦护理中的道德维度：一项系统综述
Carlijn Damsté and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag059, https://doi.org/10.1093/jac/dkag059
12
Extrapolation of oritavancin PK/PD targets to inform therapeutic drug monitoring: a systematic review
奥利他万星药代动力学/药效学目标的外推用以指导治疗药物监测：一项系统综述
Giammarco Baiardi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag117, https://doi.org/10.1093/jac/dkag117
ORIGINAL RESEARCH（论著）
13
Beyond plasma: defining the translation value of epithelial lining fluid exposure profiles for the treatment of pneumonia
超越血浆：明确上皮衬里液暴露谱对肺炎治疗的转化价值
Yakun Fu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf458, https://doi.org/10.1093/jac/dkaf458
14
Impact of loading dose β-lactam therapy on outcomes of KPC-producing Klebsiella pneumoniae bloodstream infections in non-ICU patients: a real world study
负荷剂量β-内酰胺类药物治疗非重症监护病房患者产KPC肺炎克雷伯菌血流感染的疗效影响：一项现实研究
Luisa Frallonardo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag087, https://doi.org/10.1093/jac/dkag087
15
Rezafungin exhibits anti-biofilm properties against fungal biofilms in vitro
雷扎芬净在体外对真菌生物膜表现出抗生物膜特性
Hafsa Abduljalil and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag058, https://doi.org/10.1093/jac/dkag058
16
Vancomycin resistance predicts increased mortality in patients with Enterococcus faecium bloodstream infections: a six-year experience at a large tertiary care Italian hospital
万古霉素耐药性可预测屎肠球菌血流感染患者死亡率增加：意大利一家大型三级医院六年来的经验
Lucia Graziani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag069, https://doi.org/10.1093/jac/dkag069
17
Fluoroquinolones and the risk of panic attacks: a systematic review and disproportionality analysis using individual case safety reports from the FDA Adverse Event Reporting System (FAERS) database
氟喹诺酮类药物与惊恐发作风险：基于美国食品药品监督管理局不良事件报告系统（FAERS）数据库中个体病例安全报告的系统综述和比例失衡分析
Keeirah Hiertika Raguram and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag083, https://doi.org/10.1093/jac/dkag083
18
Cefuroxime concentrations in facial artery musculomucosal flap, buccal submucosa, subcutaneous tissue, and plasma following bolus or continuous infusion in patients undergoing oral cancer resection: a randomized clinical microdialysis study
在接受口腔癌切除术的患者中，采用随机临床微透析研究，探究头孢呋辛在面动脉肌黏膜瓣、颊黏膜下层、皮下组织和血浆中的浓度（团注或持续输注后）
Johanne Ravn Hansen and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag085, https://doi.org/10.1093/jac/dkag085
19
Infection point of care tests bridge the experience gap of antibiotic STOP decisions: clinicians versus students
感染即时检测可弥补抗生素停药决策方面的经验差距：临床医生与学生对比
Archit Singhal and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkaf486, https://doi.org/10.1093/jac/dkaf486
20
Functional analysis of a novel macrolide–lincosamide resistance gene erm(57) in Cutibacterium avidum
痤疮丙酸杆菌中一种新型大环内酯 - 林可酰胺类耐药基因erm(57)的功能分析
Juri Koizumi and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag029, https://doi.org/10.1093/jac/dkag029
21
HIV drug resistance amongst children and adolescents with viraemia in Lesotho and Tanzania: a nested analysis in the GIVE MOVE trial
莱索托和坦桑尼亚病毒血症儿童及青少年中的HIV耐药性：GIVE MOVE试验的嵌套分析
Christof Manuel Schönenberger and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag070, https://doi.org/10.1093/jac/dkag070
22
Identification and assessment of paediatric cefepime-induced neurotoxicity in a retrospective cohort of paediatric intensive care patients
在儿科重症监护患者回顾性队列中识别和评估儿科头孢吡肟诱导的神经毒性
Kathryn Pavia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag075, https://doi.org/10.1093/jac/dkag075
23
Prioritization of adverse events related to integrase inhibitors and NNRTIs: a disproportionality analysis using data from the FAERS database
整合酶抑制剂和非核苷类逆转录酶抑制剂相关不良事件的优先级排序：基于FAERS数据库数据的比例失衡分析
Gao-yang Wang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag074, https://doi.org/10.1093/jac/dkag074
24
Clinical and immunovirological status in children, adolescents and young adults with early-life-acquired HIV: a Spanish multi-cohort analysis since 2020
自2020年以来西班牙多队列分析中，儿童、青少年及青年时期感染HIV者的临床及免疫病毒学状态
Laura Tarancon-Diez and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag079, https://doi.org/10.1093/jac/dkag079
25
Population pharmacokinetics of meropenem in critically ill adult patients receiving extracorporeal membrane oxygenation—an ASAP ECMO study
接受体外膜肺氧合治疗的危重成年患者美罗培南的群体药代动力学——一项ASAP ECMO研究
Mohd H Abdul–Aziz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag090, https://doi.org/10.1093/jac/dkag090
26
Evaluation of HIV-1 transmitted drug-resistance among subtypes circulating from 2022 to 2024 in Italy: a refined analysis through next-generation sequencing
2022年至2024年意大利流行HIV-1亚型间传播耐药性的评估：通过下一代测序技术进行的精细分析
Daniele Armenia and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag084, https://doi.org/10.1093/jac/dkag084
27
Characterization of efflux pump channel of florfenicol for resistance-enhancing variant RE-CmeABC in Campylobacter
耐药增强型变异体RE-CmeABC中氟苯尼考外排泵通道在弯曲菌中的特性研究
Hong Yao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag047, https://doi.org/10.1093/jac/dkag047
28
Genomic characterization of colistin heteroresistance in Acinetobacter baumannii: Evidence for lpxD deletion and collateral sensitivity
鲍曼不动杆菌中黏菌素异质性耐药的基因组特征：lpxD缺失及附带敏感性的证据
Banu Sancak and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag076, https://doi.org/10.1093/jac/dkag076
29
Sustaining stewardship: longitudinal evaluation of an integrated antimicrobial programme in the ICU
持续管理：重症监护室（ICU）综合抗菌药物管理项目的纵向评估
Ashmitha Thomas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag086, https://doi.org/10.1093/jac/dkag086
30
Global dissemination of optrA-mediated linezolid resistance in enterococci
利奈唑胺耐药性基因optrA介导的肠球菌在全球的传播
Jia Qi Beh and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag089, https://doi.org/10.1093/jac/dkag089
31
Predicting oral cephalosporin susceptibility in Escherichia coli blood isolates using parenteral cephalosporin susceptibility testing
利用肠外头孢菌素敏感性试验预测大肠杆菌血培养分离株对口服头孢菌素的敏感性
Tho H Pham and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag093, https://doi.org/10.1093/jac/dkag093
32
The pharmacodynamics of polymyxin B in Acinetobacter baumannii in murine thigh and lung infection models
在小鼠大腿和肺部感染模型中多粘菌素B对鲍曼不动杆菌的药效动力学研究
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag097, https://doi.org/10.1093/jac/dkag097
33
Genomic insights into the tmexCD-toprJ: plasmid-mediated evolution, dissemination and diversity in bacterial populations
关于tmexCD-toprJ的基因组见解：质粒介导的细菌群体进化、传播与多样性
Lilan Wan and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag107, https://doi.org/10.1093/jac/dkag107
34
Baseline resistance mutations and virological response to dolutegravir in treatment-naïve patients: a multicentre NGS study
初治患者基线耐药突变与多替拉韦病毒学应答：一项多中心下一代测序（NGS）研究
Alexy Inciarte and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag080, https://doi.org/10.1093/jac/dkag080
35
Novel integrase mutations linked to genotypic DTG resistance in African non-B HIV-1 strains: the DTG RESIST study
非洲非B型HIV-1毒株中与多替拉韦（DTG）基因型耐药相关的新型整合酶突变：DTG耐药研究
Nuri Han and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag088, https://doi.org/10.1093/jac/dkag088
36
Pharmacological evaluation of an ex vivo cervicovaginal HIV prevention model
体外宫颈阴道HIV预防模型的药理学评估
Lindsey B Collins and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag103, https://doi.org/10.1093/jac/dkag103
37
The magnitude of the pharmacodynamic index for NOSO-502: pathogen clearance, emergence of resistance and human dose predictions
NOSO-502药效学指数的幅度：病原体清除、耐药性出现和人体剂量预测
Sanne van den Berg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag106, https://doi.org/10.1093/jac/dkag106
38
Temocillin: a therapeutic alternative in bone and joint infections due to third generation cephalosporin-resistant Enterobacterales?
替莫西林：治疗第三代头孢菌素耐药肠杆菌目引起的骨关节感染的一种替代疗法？
Louise Piquart and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag105, https://doi.org/10.1093/jac/dkag105
39
Metallo-β-lactamase–producing Enterobacterales: cyanide-containing efflux pump inhibitors as potential dual-activity inhibitors
产金属β-内酰胺酶的肠杆菌科细菌：含氰化物的外排泵抑制剂作为潜在的双活性抑制剂
Otávio Hallal Ferreira Raro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag122, https://doi.org/10.1093/jac/dkag122
40
Outer membrane vesicles transmit blaNDM-5 and package metallo-β-lactamases to promote antibiotic resistance in Escherichia coli
外膜囊泡传递blaNDM-5并包装金属β-内酰胺酶以促进大肠杆菌的抗生素耐药性
Ting-Yin Lu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag123, https://doi.org/10.1093/jac/dkag123
41
Characterization of a ST412-K57 colistin-resistant hypervirulent Klebsiella pneumoniae strain of chicken origin
一株鸡源ST412-K57多粘菌素耐药高毒力肺炎克雷伯菌的特征分析
Qiu Xu and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag114, https://doi.org/10.1093/jac/dkag114
42
Olorofim in combination with azole antifungals: results from the Phase 2 salvage therapy study
奥罗芬明与唑类抗真菌药联合使用：2期挽救治疗研究结果
Johan Maertens and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag118, https://doi.org/10.1093/jac/dkag118
RESEARCH LETTER（研究快讯）
43
Infant HIV transmission despite maternal viral suppression: a case of post-weaning seroconversion
母体病毒得到抑制，婴儿仍发生HIV传播：一例断奶后血清转阳病例
Shadia Nakalema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag072, https://doi.org/10.1093/jac/dkag072
44
Urinary antigen–negative Legionella pneumonia in critically ill patients: value of systematic molecular testing for optimal antimicrobial therapy
危重患者中尿抗原阴性军团菌肺炎：系统分子检测在优化抗菌治疗中的价值
Livia Foglia Manzillo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag101, https://doi.org/10.1093/jac/dkag101
45
Contribution of SHV-1 overexpression to carbapenem resistance in a Klebsiella pneumoniae clinical isolate
SHV-1过表达对某株肺炎克雷伯菌临床分离株碳青霉烯类抗生素耐药性的影响
Céline Plainvert and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag108, https://doi.org/10.1093/jac/dkag108
LETTER TO THE EDITOR（致编辑的信）
46
Comment on: Possible increased risk of Epstein–Barr virus (EBV) infection and posttransplant lymphoproliferative disease (PTLD) in letermovir-exposed haematopoietic cell transplantation recipients
评论：接受莱特莫韦治疗的造血细胞移植受者中，EB病毒（EBV）感染和移植后淋巴增殖性疾病（PTLD）的风险可能增加
Jan Styczynski
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag042, https://doi.org/10.1093/jac/dkag042
47
Comment on: Antimicrobial use for the treatment of bacterial sexually transmitted infections among doxycycline post-exposure prophylaxis users in Milan, Italy
评论：意大利米兰地区使用多西环素暴露后预防措施人群中针对细菌性性传播感染的抗菌药物使用情况
Luca Bortolani and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag023, https://doi.org/10.1093/jac/dkag023
48
Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes—right to reply
使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净药物治疗监测的回顾性分析——答复权
Antoine Hérault and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag095, https://doi.org/10.1093/jac/dkag095
49
Comment on: Temocillin versus other intravenous beta-lactams for urinary tract infections caused by third-generation cephalosporin-resistant Enterobacterales: a multicentre retrospective matched-cohort study
评论：替莫西林与其他静脉注射β-内酰胺类抗生素治疗第三代头孢菌素耐药肠杆菌目引起的尿路感染：一项多中心回顾性匹配队列研究
Shanshan Ru and Yingzhe Zhang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag096, https://doi.org/10.1093/jac/dkag096
50
Comment on: Long-acting glycopeptides: what are the barriers to access in patients who need them most, and how can they be overcome?
评论：长效糖肽类抗生素：对于最需要它们的患者，获取的障碍是什么，如何克服？
Marco Bongiovanni
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag102, https://doi.org/10.1093/jac/dkag102
51
Comment on ‘Retrospective analysis of pharmacological therapeutic monitoring of caspofungin in patients undergoing continuous renal replacement therapy using polyacrylonitrile membranes’
评论：“对使用聚丙烯腈膜进行连续肾脏替代治疗的患者中卡泊芬净的药理学治疗监测的回顾性分析”
Julien Massol and Frédéric Baud
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag094, https://doi.org/10.1093/jac/dkag094
52
Comment on: ‘Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp’
对“除塞拉蒂亚属（Serratia spp）外肠杆菌目所致心内膜炎的流行病学和治疗”的评论
Gianpiero Tebano and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag098, https://doi.org/10.1093/jac/dkag098
53
‘Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–2021-right-to-reply’
“比较肺炎球菌疫苗的血清型覆盖率——PCV21（V116，一种新型21价结合肺炎球菌疫苗）与加拿大成人患者中导致侵袭性肺炎球菌疾病的其8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学：SAVE研究，2018 - 2021年——回应”
John J Schellenberg and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag126, https://doi.org/10.1093/jac/dkag126
54
Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus
评论：奥罗芬明与伏立康唑对烟曲霉的体外拮抗作用
Corinne Pinder and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag119, https://doi.org/10.1093/jac/dkag119
55
Epidemiology and treatment of endocarditis secondary to Enterobacterales other than Serratia spp.: right-to-reply
除塞氏杆菌属外肠杆菌科细菌所致心内膜炎的流行病学和治疗：回应
Sunish Shah and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 4, April 2026, dkag121, https://doi.org/10.1093/jac/dkag121
Journal of Antimicrobial Chemotherapy Volume 81, Issue 5抗菌化疗杂志81卷 5期
https://academic.oup.com/jac/issue
50TH ANNIVERSARY COLLECTION（50周年纪念合集）
REVIEW（综述）
1
A strategic discovery roadmap towards high-quality leads and drug development candidates for kinetoplastid diseases. Part 1: setting the stage
针对动基体病的高质量先导化合物及药物开发候选物的战略发现路线图。第一部分：背景介绍
Sarah Hendrickx and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag109, https://doi.org/10.1093/jac/dkag109
REVIEW（综述）
2
Pathophysiology, risk factors and clinical management for polymyxin-associated acute kidney injury
多粘菌素相关急性肾损伤的病理生理学、危险因素及临床治疗
Simiao Zhao and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag132, https://doi.org/10.1093/jac/dkag132
SYSTEMATIC REVIEW（系统综述）
3
Definitions and rates of treatment failure in females with uncomplicated urinary tract infection: a systematic literature review
女性单纯性尿路感染治疗失败的定义及发生率：一项系统文献综述
Meghan E Luck and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag112, https://doi.org/10.1093/jac/dkag112
4
Therapeutic drug monitoring and the role of pharmacokinetics/pharmacodynamics in optimizing beta-lactam antibiotic dosing for deep-seated infections: a systematic review
在针对深部感染的β-内酰胺类抗生素优化给药方案中治疗药物监测以及药代动力学/药效学的作用：一项系统综述
Cassandra Vale and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag142, https://doi.org/10.1093/jac/dkag142
ORIGINAL RESEARCH（论著）
5
Optimizing cloxacillin prophylaxis in hip and knee arthroplasty based on population pharmacokinetics of unbound plasma concentrations
基于游离血浆浓度群体药代动力学优化髋关节和膝关节置换术中的氯唑西林预防用药方案
Gustaf Beijer and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag116, https://doi.org/10.1093/jac/dkag116
6
The tissue distribution and pharmacokinetics of [14C]-olorofim following intravenous dosing in the rat
大鼠静脉注射[14C]奥洛罗芬后的组织分布及药代动力学研究
Derek Law and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag120, https://doi.org/10.1093/jac/dkag120
7
Insights from the WHO Tricycle-aligned Fleming Fund EQASIA External Quality Assessment (EQA) programme detecting ESBL-, AmpC- and carbapenemase-producing Escherichia coli in South and South-East Asia
世界卫生组织三轮车项目（Tricycle）协同的弗莱明基金南亚和东南亚地区外部质量评估（EQASIA EQA）计划在检测南亚和东南亚地区产超广谱β-内酰胺酶（ESBL）、AmpC酶和碳青霉烯酶的大肠埃希菌方面的见解
Hiba Al-Mir and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag129, https://doi.org/10.1093/jac/dkag129
8
The plasma and intracellular exposure of intramuscularly administered long-acting cabotegravir and rilpivirine in people with HIV
HIV感染者肌内注射长效卡博特韦和利匹韦林后的血浆及细胞内暴露情况
Micol Ferrara and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag113, https://doi.org/10.1093/jac/dkag113
9
In vitro synergistic activity of minocycline and biapenem against cefiderocol-resistant New Delhi metallo-β-lactamase-producing Enterobacterales
米诺环素与比阿培南在体外对产新德里金属β-内酰胺酶且对头孢地尔耐药的肠杆菌科细菌的协同作用
Takashi Okanda and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag128, https://doi.org/10.1093/jac/dkag128
10
Mortality risk of ESBL producers in Escherichia coli bacteraemia: a comprehensive analysis using the PROBAC cohort
产超广谱β-内酰胺酶大肠埃希菌菌血症的死亡风险：基于PROBAC队列的综合分析
Paula Olivares-Navarro and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag130, https://doi.org/10.1093/jac/dkag130
11
Molecular mechanism of envZ regulating β-lactam antibiotic resistance and virulence in Escherichia coli
EnvZ调控大肠埃希菌β-内酰胺类抗生素耐药性及毒力的分子机制
Kun Yang and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag104, https://doi.org/10.1093/jac/dkag104
12
In vitro activity of amoxicillin combined with oral cephalosporins against endocarditis-associated E. faecalis clinical isolates
阿莫西林联合口服头孢菌素针对心内膜炎相关粪肠球菌临床分离株的体外活性
David Luque Paz and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag127, https://doi.org/10.1093/jac/dkag127
13
Genome-wide association studies builds a predictive model and reveals novel resistance features for macrolide-resistant Bordetella pertussis
全基因组关联研究构建预测模型并揭示大环内酯类耐药百日咳鲍特菌的新耐药特征
Jialiang Chen and Guowei Liang
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag131, https://doi.org/10.1093/jac/dkag131
14
Real-world validation of a reduced-dose continuous infusion cefepime regimen: pharmacodynamic target attainment, efficacy and neurotoxicity
减量持续静脉输注头孢吡肟方案的实际应用验证：药效学目标达成情况、疗效及神经毒性
Kieffer Korvin and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag138, https://doi.org/10.1093/jac/dkag138
15
Cross-species and cross-border spread of aph(3′)-ia-mediated neomycin resistance in Escherichia coli from animals: a genomic perspective
从基因组角度研究动物源大肠杆菌中aph(3′)-ia介导的新霉素耐药性的跨物种和跨国传播
Mattia Pirolo and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag143, https://doi.org/10.1093/jac/dkag143
16
Prevalence of cyp51A variants in a US collection of Aspergillus fumigatus clinical isolates and comparative analysis of their contribution to triazole antifungal resistance
美国烟曲霉临床分离株集合中cyp51A变异体的流行情况及其对三唑类抗真菌药物耐药性作用的比较分析
Luisa Fernanda Gómez Londoño and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag124, https://doi.org/10.1093/jac/dkag124
17
In vitro and in vivo activity of daptomycin plus ceftaroline for the treatment of experimental endocarditis due to Enterococcus faecalis with and without high-level aminoglycoside resistance
达托霉素联合头孢洛林对高水平氨基糖苷类耐药及非耐药粪肠球菌所致实验性心内膜炎的体内外疗效研究
María-Alexandra Cañas and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag136, https://doi.org/10.1093/jac/dkag136
18
Pharmacokinetics of a three-dose regimen of intramuscular benzathine penicillin G in pregnant women with syphilis
三剂苄星青霉素G肌内注射方案在妊娠期梅毒患者中的药代动力学研究
Eshetie Melese Birru and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag145, https://doi.org/10.1093/jac/dkag145
19
Cefiderocol resistance mediated by mutation of the miniconductance mechanosensitive channel MscM in Klebsiella oxytoca
由产气克雷伯菌中微小电导机械敏感通道MscM发生突变所介导的头孢地尔耐药性
Pia Turowski and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag147, https://doi.org/10.1093/jac/dkag147
20
The veterinary clinic backyard lawn used for relief walks of hospitalized dogs is a hotspot for OXA-type carbapenemases in multiple Enterobacterales
兽医诊所后院供住院犬只散步的草坪是多种肠杆菌科细菌中OXA型碳青霉烯酶的传播热点区域
Yvonne Spahr and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag144, https://doi.org/10.1093/jac/dkag144
21
Pharmacokinetics of cefazolin in bariatric surgery patients: a preoperative perspective
头孢唑林在减肥手术患者中的药代动力学：术前视角
Alexandra Porlier and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag150, https://doi.org/10.1093/jac/dkag150
RESEARCH LETTERS（研究快讯）
22
Plasmid-encoded FRI-10 carbapenemase harboured by non-Enterobacter species isolated from a wastewater sample in Tokyo, Japan
从日本东京废水样本中分离出的非肠杆菌科物种携带质粒编码的FRI-10碳青霉烯酶
Kou Murakami and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag133, https://doi.org/10.1093/jac/dkag133
23
Synergistic activity of cefepime/enmetazobactam with meropenem, piperacillin, piperacillin/tazobactam, cefiderocol and fosfomycin against Klebsiella pneumoniae carrying blaKPC allelic variants
头孢吡肟/恩美唑巴坦与美罗培南、哌拉西林、哌拉西林/他唑巴坦、西他沙星和磷霉素针对携带blaKPC等位基因变体的肺炎克雷伯菌的协同作用
Alice Crema and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag141, https://doi.org/10.1093/jac/dkag141
24
MRSA and carbapenem-resistant Acinetobacter baumannii on the fall: successful infection prevention and control in Chilean ICUs
耐甲氧西林金黄色葡萄球菌和耐碳青霉烯类鲍曼不动杆菌数量下降：智利重症监护病房感染预防与控制的成功案例
Patricio Ross and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag146, https://doi.org/10.1093/jac/dkag146
LETTER TO THE EDITOR（致编辑的信）
25
Comment on: Model-based assessment of VRC07-523LS dosing in infants through population pharmacokinetic–pharmacodynamic modelling in adults and infants
评论：基于模型的评估VRC07-523LS在婴儿中的给药剂量——基于成人和婴儿群体药代动力学-药效学模型
Wanhua Qiu
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag139, https://doi.org/10.1093/jac/dkag139
26
Comment on: Comparing serotype coverage of pneumococcal vaccines with PCV21 (V116), a new 21-valent conjugate pneumococcal vaccine, and the epidemiology of its eight unique Streptococcus pneumoniae serotypes (15A, 15C, 16F, 23A, 23B, 24F, 31 and 35B) causing invasive pneumococcal disease in adult patients in Canada: SAVE study, 2018–21
评论：比较含21种血清型的肺炎球菌疫苗PCV21（V116）（一种新型21价结合肺炎球菌疫苗）的血清型覆盖范围，以及2018 - 2021年SAVE研究中导致加拿大成年患者侵袭性肺炎球菌疾病的8种独特肺炎链球菌血清型（15A、15C、16F、23A、23B、24F、31和35B）的流行病学情况
Gokul Raj Pullagura and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag125, https://doi.org/10.1093/jac/dkag125
27
Comment on: Distinct population structure and genomic context of NarAB between broiler and human clinical Enterococcus isolates
评论：肉鸡源和人临床来源肠球菌分离株中NarAB的不同种群结构和基因组背景
Alex Wong
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag134, https://doi.org/10.1093/jac/dkag134
28
Distinct population structure and genomic context of narAB between broiler and human clinical Enterococcus isolates—authors’ response
肉鸡源和人临床来源肠球菌分离株中narAB的不同种群结构和基因组背景——作者回复
Jayanth Balakuntla and others
Journal of Antimicrobial Chemotherapy, Volume 81, Issue 5, May 2026, dkag135, https://doi.org/10.1093/jac/dkag135
100 项与 两性霉素B 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 利什曼病 | 日本 | 2009-06-17 | |
| 粒细胞减少性发热 | 日本 | 2006-04-20 | |
| 念珠菌病 | 日本 | 1997-01-31 | |
| 侵袭性真菌感染 | 日本 | 1963-04-18 | |
| 真菌病 | - | 1958-01-01 | |
| 复杂的尿路感染 | 中国 | - | - |
| 细菌性心内膜炎 | 中国 | - | - |
| 脑膜炎 | 中国 | - | - |
| 脓毒症 | 中国 | - | - |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 隐球菌脑膜炎 | 临床3期 | - | 2023-01-01 | |
| 肺部疾病 | 临床3期 | 美国 | 2005-10-01 | |
| 侵袭性念珠菌病 | 临床2期 | - | 2020-01-01 | |
| 侵袭性曲霉菌病 | 临床2期 | - | 2020-01-01 | |
| 急性淋巴细胞白血病 | 临床2期 | - | 2019-08-01 | |
| 急性髓性白血病 | 临床2期 | - | 2019-08-01 | |
| 外阴阴道念珠菌病 | 临床2期 | 美国 | 2016-11-01 | |
| 酵母菌感染 | 临床2期 | 美国 | 2016-11-01 | |
| 慢性皮肤黏膜念珠菌病 | 临床2期 | 美国 | 2016-09-27 | |
| 口腔念珠菌病 | 临床2期 | 美国 | 2001-08-31 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 854 | SDD prophylaxis | 壓窪壓餘衊膚艱構願夢(廠憲襯襯壓糧獵壓窪廠) = 鑰遞鏇範網願遞觸憲築 鑰膚艱網衊蓋蓋齋艱繭 (淵繭築網餘築構鏇窪艱 ) | 积极 | 2025-12-04 | ||
N/A | 32 | ABCD nebulized inhalation combined with intravenous injection | 範餘憲廠築窪繭廠選構(齋網獵襯鑰蓋遞蓋網夢) = slightly lower in the combined therapy group than in the intravenous therapy group (1675 vs 1800, P=0.611), although the difference was not statistically significant. 築築鹹鏇齋鹹簾糧夢願 (簾鑰淵鹹淵膚蓋廠淵齋 ) 更多 | 积极 | 2025-07-01 | ||
ABCD intravenous injection | |||||||
N/A | 503 | 淵積膚窪鹹餘夢壓範願(遞網衊鹹窪遞獵齋鹽夢) = 衊壓窪壓膚獵願廠顧淵 鏇艱鹽糧獵蓋鹹淵醖艱 (網醖製繭網鑰襯膚獵淵 ) 更多 | 积极 | 2025-05-01 | |||
临床2期 | 118 | single dose of L-AmB (Single Dose of L-AmB) | 簾簾糧衊積淵衊簾觸膚 = 醖鹽窪鹽構鏇窪醖蓋廠 膚齋餘獵簾淵齋選選鹽 (願襯築夢夢鹽繭糧窪製, 選製網膚遞醖選壓餘鏇 ~ 醖製衊築鏇醖壓築蓋顧) 更多 | - | 2025-03-14 | ||
(2 Doses of L-AmB) | 簾簾糧衊積淵衊簾觸膚 = 夢繭構積範夢衊顧艱鑰 膚齋餘獵簾淵齋選選鹽 (願襯築夢夢鹽繭糧窪製, 築壓積鹽鏇選鏇鹹範蓋 ~ 選鹹選積繭鏇範窪襯淵) 更多 | ||||||
临床4期 | 55 | 顧糧醖簾網鬱構鹹鑰衊(淵構獵艱範鬱蓋範餘積) = 糧淵鬱獵簾憲衊餘網願 糧齋齋餘夢醖構範齋鏇 (製襯鬱簾構簾蓋膚壓糧 ) 更多 | 积极 | 2025-03-11 | |||
临床1/2期 | 隐球菌脑膜炎 human immunodeficiency virus (HIV) | 498 | Liposomal Amphotericin B | 鹹範獵淵蓋觸鹹淵鏇選(選壓憲廠構簾憲餘簾簾) = 夢積製鹹鑰繭網觸繭醖 鹹觸製衊艱廠膚壓衊築 (艱鑰鏇鬱繭淵製顧夢繭, 0.355 ~ 0.634) 更多 | 积极 | 2025-02-05 | |
鹹範獵淵蓋觸鹹淵鏇選(選壓憲廠構簾憲餘簾簾) = 壓鬱範衊製築鬱蓋糧糧 鹹觸製衊艱廠膚壓衊築 (艱鑰鏇鬱繭淵製顧夢繭, 0.360 ~ 0.445) 更多 | |||||||
临床2期 | 4 | 鏇網構窪鑰衊繭願範鏇 = 艱觸廠構醖繭網積構構 鑰壓壓壓憲願遞壓憲觸 (夢衊廠網蓋醖餘糧蓋襯, 壓選夢蓋壓製鏇簾蓋積 ~ 廠遞顧齋繭廠遞壓積鬱) 更多 | - | 2024-06-07 | |||
N/A | 21 | (Group A (poor response to other antifungal drugs)) | 窪製積繭鏇鏇襯廠網鏇(鑰鬱鏇顧淵憲選簾製齋) = 製蓋鬱顧選鏇簾壓簾衊 艱製憲鬱壓選醖夢選繭 (鬱選醖鏇夢鹹製構鹽選 ) | 积极 | 2024-05-14 | ||
(Group B (cannot tolerate adverse reactions)) | 窪製積繭鏇鏇襯廠網鏇(鑰鬱鏇顧淵憲選簾製齋) = 獵顧淵積築糧製鹽網壓 艱製憲鬱壓選醖夢選繭 (鬱選醖鏇夢鹹製構鹽選 ) | ||||||
GlobeNewswire 人工标引  | N/A | 3 | 繭鹹憲鑰築憲蓋糧糧醖(獵積製艱糧膚顧製鑰窪) = 夢網簾網鑰鑰積衊鹽糧 選淵鏇鏇顧壓遞醖衊鹹 (衊齋夢遞憲顧網廠窪繭 ) | 积极 | 2024-03-22 | ||
GlobeNewswire 人工标引 | N/A | 19 | 廠積廠鑰顧夢繭範膚糧(構獵齋蓋膚積憲網選醖) = 餘窪願糧鑰鹽襯鏇積淵 淵觸選選憲窪範範範憲 (衊廠繭蓋夢艱繭築醖構 ) 更多 | 积极 | 2024-02-26 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用